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RESUMO 
Esclerose lateral amiotrófica (ELA) é uma doença neurodegenerativa fatal caracterizada pela per-
da progressiva de neurónios motores (NMs). Estudos apontam as células gliais como factores cruci-
ais na origem e progressão da doença. De facto, vias de sinalização NM-microglia envolvendo neuro-
protecção ou inflamação, são susceptíveis de estarem alteradas na ELA. 
Neste trabalho procurámos estudar moléculas relacionadas com função glial e/ou reactividade pe-
la avaliação de marcadores gliais e hemicanais, maioritariamente expressos nos astrócitos. Adicio-
nalmente, estudámos moléculas envolvidas no diálogo NM-microglia (CXCR3/CCL21; 
CX3CR1/CX3CL1; MFG-E8), assim como na proliferação (Ki-67), moléculas envolvidas em inflama-
ção (TLR2/4, NLRP3; IL-18) e em sinais de alarme/calmantes (HMGB1/autotaxin). Para tal usámos 
homogeneizados de medula espinhal lombar de ratinhos que expressam a proteína humana mutada 
SOD1 (mSOD1) num estadio pré-sintomático e sintomático de ELA. Ratinhos SJL (WT) com as mes-
mas idades foram usados como controlos. 
Observámos expressão reduzida de genes associados a marcadores astrocitários (GFAP e 
S100B) e microgliais (CD11b) em mSOD1 na fase pré-sintomática, assim como níveis diminuídos de 
componentes de junções aderentes, panexina1 e conexina43, e expressão de Ki-67 e autotaxina di-
minuída. Adicionalmente, o diálogo NM-microglia estava reduzido em ratinhos mSOD1 assim como a 
resposta inflamatória. Curiosamente, observámos reactividade asctrocítica (S100B) e microglial 
(CD11b) aumento da proliferação (Ki-67) e expressão de autotaxina diminuída em ratinhos mSOD1 
sintomáticos. Diálogo NM-microglia (CXCR3/CCL21; CX3CR1/CX3CL1; MFG-E8) e actividade de 
hemicanais (conexina43 e panexina1) foram observados na fase sintomática, juntamente com respos-
ta inflamatória exacerbada, assim indicada pelos níveis aumentados de HMGB1 e NLRP3. 
Os nossos resultados sugerem que a diminuição da expressão de autotaxina constitui uma carac-
terística da fase pré-sintomática, e precede a rede de determinantes inflamatórios na fase sintomáti-
ca, incluindo HMGB1, CCL21, CX3CL1, e NLRP3. Identificação de moléculas e vias de sinalização 
que estão diferencialmente activadas durante a progressão da ELA vão contribuir para um melhor 
desenvolvimento de estratégias terapêuticas para a doença. 
 
Termos-chave: esclerose lateral amiotrófica; neurodegeneração; diálogo neurónio motor-microglia; 
neuroinflamação; modelo ratinho G93ASOD1 
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ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the pro-
gressive loss of motoneurons (MN). Increasing evidence points glial cells as key players for ALS onset 
and progression. Indeed, MN-glia signalling pathways involving either neuroprotection or inflammation 
are likely to be altered in ALS. 
We aimed to study the molecules related with glial function and/or reactivity by evaluating glial 
markers and hemichannels, mainly present in astrocytes. We also studied molecules involved in mi-
croglia-MN dialogue (CXCR3/CCL21; CX3CR1/CX3CL1; MFG-E8), as well as proliferation (Ki-67) and 
inflammatory-related molecules (TLR2/4, NLRP3; IL-18) and alarming/calming signals 
(HMGB1/autotaxin). We used lumbar spinal cord (SC) homogenates from mice expressing a mutant 
human-SOD1 protein (mSOD1) at presymptomatic and late-symptomatic ALS stages. SJL (WT) mice 
at same ages were used as controls. 
We observed decreased expression of genes associated with astrocytic (GFAP and S100B) and 
microglial (CD11b) markers in mSOD1 at the presymptomatic phase, as well as diminished levels of 
gap junction components pannexin1 and connexin43 and expression of Ki-67 and decreased autotax-
in. In addition, microglial-MN communication was negatively affected in mSOD1 mice as well as in-
flammatory response. Interestingly, we observed astrocytic (S100B) and microglial (CD11b) reactivity, 
increased proliferation (Ki-67) and increased autotaxin expression in symptomatic mSOD1 mice. In-
creased MN-microglial dialogue (CXCR3/CCL21; CX3CR1/CX3CL1; MFG-E8) and hemichannel activ-
ity, namely connexin43 and pannexin1, were also observed in mSOD1 at the symptomatic phase, 
along with an elevated inflammatory response as indicated by increased levels of HMGB1 and 
NLRP3.  
Our results suggest that decreased autotaxin expression is a feature of the presymptomatic stage, 
and precede the network of pro-inflammatory-related symptomatic determinants, including HMGB1, 
CCL21, CX3CL1, and NLRP3. The identification of the molecules and signaling pathways that are dif-
ferentially activated along ALS progression will contribute for a better design of therapeutic strategies 
for disease onset and progression.  
 
Keywords: amyotrophic lateral sclerosis; neurodegeneration; glial-motoneuron dialogue; neuroin-
flammation; G93ASOD1 mouse model 
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Chapter I. INTRODUCTION 
1 
I. INTRODUCTION 
1. Amyotrophic lateral sclerosis: an overview 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by selective loss 
of upper motoneurons (UMN) in the cortex and in the brainstem and lower motoneurons (LMN) in the 
spinal cord (SC) of the patients, which progressively leads to muscle atrophy and paralysis and ulti-
mately death, usually by respiratory failure (Liao et al., 2012; Pratt et al., 2012; Robberecht and 
Philips, 2013). This disease was first described in 1869 by the French neurologist Jean-Martin Charcot 
and can sometimes be referred to as Lou Gehrig’s disease (Gonzalez de Aguilar et al., 2007). Etymo-
logically, ALS refers to the lack of muscle nourishment (amyotrophic), lateral meaning the corticospinal 
tract which descends through the lateral spinal cord and sclerosis meaning hardening or scarring 
(Bento-Abreu et al., 2010). The onset of ALS is about 50 to 60 years of age, although it may occur 
earlier in life, with a life expectancy of 3 to 5 years after symptoms onset (Kiernan et al., 2011; Mitchell 
and Borasio, 2007). This disease is the most common adult-onset motoneuron disorder, affecting ap-
proximately 1-2 people per 100,000 individuals worldwide (Factor-Litvak et al., 2013) with men being 
slightly more affected than women by a factor between 1.2 and 1.5 (Al-Chalabi and Hardiman, 2013), 
and approximately 5,600 people are diagnosed each year (Gilbert, 2014). Although there are no epi-
demiological studies of ALS in Portugal, according to Professor Mamede de Carvalho clinical practice 
(a renowned clinician in the area of ALS in Portugal at Centro Hospitalar Lisboa-Norte – Hospital de 
Santa Maria) it is estimated that there are 600 Portuguese patients suffering from this disease, with a 
tendency to increase due to population aging. ALS has an array of clinical manifestations which over-
lap with other neurodegenerative diseases which makes the diagnosis very difficult and until now there 
is no definitive diagnosis for the disease (Hardiman et al., 2011; Robberecht and Philips, 2013). The 
main presentations, according to the location where the disease begins, include: (1) limb-onset ALS, 
more common, with a combination of UMN and LMN signs in the limbs; (2) bulbar-onset ALS, present-
ing speech and swallowing difficulties, and with limb features developing later in the course of the dis-
ease; (3) the less common primary lateral sclerosis with pure UMN involvement; and (4) progressive 
muscular atrophy, with pure LMN involvement (Figure I.1.) (Kiernan et al., 2011). Currently, riluzole 
(Rilutek®) is the only drug approved by the United States Food and Drug Administration (FDA), alt-
hough it was proven that this drug slows disease progression by extending patient survival only by 2-3 
months (Gordon, 2013; McGeer and McGeer, 2005).  
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Figure I.1. Amyotrophic lateral sclerosis (ALS) selectively affects lower motor neurons (MN) from the ven-
tral horn of the spinal cord and brainstem and upper MN from the motor cortex. Main presentations of ALS 
include (1) limb-onset ALS, more common, with a combination of UMN and LMN signs in the limbs; (2) bulbar-
onset ALS, presenting speech and swallowing difficulties, and with limb features developing later in the course of 
the disease; (3) the less common primary lateral sclerosis with pure UMN involvement; and (4) progressive mus-
cular atrophy, with pure LMN involvement. Adapted from Kiernan et al. (2011). 
 
1.1. Genetic features 
Approximately 10% of ALS cases have genetic origin (also designated familial ALS, or fALS) 
(Kurland and Mulder, 1955a, b) following a predominantly autosomal dominant pattern (Chen et al., 
2013), while the majority of ALS cases (90%) are non-genetic, also designated as sporadic ALS  
(sALS), as reviewed in Julien (2001). Currently there are 32 genes reported as being involved in ALS 
(Abel, 2014) and mutations in some can lead to disease and some might increase susceptibility 
(Robberecht and Philips, 2013). Both fALS and sALS have common pathological mechanisms with 
indistinguishable clinical features along disease progression, as well as similar dysfunctional features 
(Calvo et al., 2012; Li et al., 1988; Phatnani et al., 2013).  
Therefore, studies of fALS can be informative either for both sporadic and familial ALS pathology. 
The copper/zinc superoxide dismutase 1 (SOD1) was the first gene (in 1993) to be identified as being 
mutated in ALS (Rosen et al., 1993) and accounts for 10-20% of fALS cases (Ticozzi et al., 2011). 
There are currently 178 different mutations spanning all five exons that have been identified in the 
SOD1 gene (Abel, 2014). Most of these mutations are missense with a dominant pattern of inheritance 
(Robberecht and Philips, 2013). Interestingly, the mutation D90A in Scandinavian populations is char-
acterized by a recessive pattern of inheritance and produce a distinctive phenotype (Pasinelli and 
Brown, 2006). This enzyme is a ubiquitous, predominantly cytosolic protein that catalyzes the dismuta-
tion of superoxide anion radicals leading to the formation of hydrogen peroxide (Bendotti et al., 2012; 
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Shaw, 2005). SOD1 functions as a homodimer, in which each monomer binds one zinc and one cop-
per atom. Copper binding is thought to be important for catalytic activity while zinc binding is believed 
to be critical for structural stability (Bendotti et al., 2012; Shaw, 2005). The mechanisms through which 
the expression of mutant SOD1 (mSOD1) results in MN injury and death involves misfolding of 
mSOD1 and escapes the ubiquitin-proteasome system whilst having an apparently toxic effect on the 
cell (Robberecht and Philips, 2013). The acquisition of the toxic function might reside in the propensity 
of mutant enzymes to form insoluble aggregates hindering intracellular functions or in a novel enzy-
matic activity, prompting a pro-oxidative chemistry in a typical anti-oxidant enzyme, or both (Bendotti 
and Carri, 2004). 
Other genes in which mutations can lead to adult-onset ALS include fused in sarcoma/translated in 
liposarcoma (FUS/TLS) (Kwiatkowski et al., 2009; Vance et al., 2009) and TAR DNA-binding protein 
(TDP-43) (Rutherford et al., 2008; Sreedharan et al., 2008). These are multifunctional proteins related 
to gene expression, RNA splicing, transport and translation. TDP-43 is reported to participate in 
mRNA transport to synapses followed by local protein synthesis in neurons, thus playing a crucial role 
in maintenance of the synaptic activity/function (Lattante et al., 2013). They are also responsible for 
the processing of microRNAs (miRNAs), RNA maturation and splicing (Colombrita et al., 2011). ALS-
causing mutations in both genes result in the movement of mutant proteins from their normal location 
in the nucleus to the cytoplasm, where they form inclusions. In fact, in vitro studies show that mutant 
TDP-43 has an inherent tendency to aggregate as mutant TDP-43, but not wild-type (WT) (Lattante et 
al., 2013). However, it is still unclear whether the cytoplasmic inclusions are themselves toxic to the 
cells or act to sequester protein, thereby reducing the pool of functional protein, (Barber and Shaw, 
2010; Pratt et al., 2012; Robberecht and Philips, 2013). 
Most recently, the discovery of C9ORF72 repeat expansion that causes ALS constituted a break-
through for ALS development (DeJesus-Hernandez et al., 2011; Renton et al., 2011). C9ORF72 con-
tains a GGGGCC hexanucleotide that is rarely repeated more than two to five times. An abnormal ex-
pansion of this sequence is found in about 40% of families with ALS and in about 7% of sALS cases. 
The normal function of the protein, presumably cytoplasmic, is unknown. The normal transcription of 
the ORF72 leads to the formation of at least three different RNAs, however, when repetitions are pre-
sent, incorrect recruitment of splicing factors occurs and leads incorrect splicing that may generate 
insoluble and potentially toxic dipeptide repeat proteins (Robberecht and Philips, 2013). 
Both the genetic and non-genetic forms of ALS are suggested to share similar pathogenic mecha-
nisms such as the presence of abnormal neurofilamentous accumulations in degenerating MNs 
(Julien, 2001). Additionally, cytoplasmic aggregation of TDP-43 and FUS are common pathological 
features of both sALS and fALS (Lagier-Tourenne et al., 2010).  
In addition, cytoplasmic aggregation of nuclear TDP-43 and FUS in the degenerating neurons and 
glia of ALS patients were recently reported, as well as the release of the accumulated mutant SOD1 to 
the extracellular space (Li et al., 2013b; Ogawa and Furukawa, 2014). 
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1.2. Environmental causes 
The fact that sALS represents approximately 90% of ALS cases suggests that specific environmen-
tal factors may play a prominent role in the pathogenesis of the disease. It has been proposed that 
exposure to cyanobacteria, heavy metals (Factor-Litvak et al., 2013), pesticides, intense physical ac-
tivity, head injury, cigarette smoking, electromagnetic fields and electrical shocks may contribute to 
ALS onset (Huisman et al., 2013; Kiernan et al., 2011; Redler and Dokholyan, 2012; Sutedja et al., 
2009; Trojsi et al., 2013). To add to the relevance of the role of toxic agents, Chamorro indigenous 
people of Guam have a high incidence rate of ALS among its population as a result of the cumulative 
consumption of cycad flour and flying foxes (Redler and Dokholyan, 2012; Trojsi et al., 2013). In par-
ticular, cycad produces the neurotoxin beta-N-methylamino-L-alanine (BMAA), the seeds are eaten by 
the flying foxes which then lead to the increase of toxin dosage in its tissues (Redler and Dokholyan, 
2012; Trojsi et al., 2013). Additionally, geographically limited populations with dramatically increased 
ALS incidence such as inhabitants of the Kii peninsula in Japan, the Chamorro people of Guam, Gulf 
War veterans and Italian football players, certainly lead one to suspect the environment as a potential 
modifier of disease susceptibility. However, no conclusive statements can be made from these few 
examples, leaving ALS risk associated with BMAA exposure to be further clarified. 
1.3. Pathogenic mechanisms involved in motoneuron susceptibility/vulnerability 
ALS is a multifactorial disease in which particular neuronal groups selectively suffer degeneration. 
Certain motor neuron populations are less vulnerable, specifically sensory and autonomic neurons 
and cerebellar neurons are almost always either preserved or affected to a very mild and subclinical 
degree (Barber and Shaw, 2010; Robberecht and Philips, 2013). Also, MNs and frontotemporal neu-
rons are affected to variable degrees (Robberecht and Philips, 2013). The underlying mechanisms 
that lead to selective death of these MNs are not fully understood, however MNs present some fea-
tures which may render this cell group vulnerable to such insults. These features include a large cell 
size with long axonal processes with a very high neurofilament content, which predicts high metabolic 
demands (Ferraiuolo et al., 2011; Shaw and Eggett, 2000). Hence, MNs rely on optimal mitochondrial 
function which potentiates the risk of oxidative stress due to the increased generation of reactive oxy-
gen species (ROS) (Ferraiuolo et al., 2011; Shaw and Eggett, 2000). MNs reveal a vulnerability to glu-
tamatergic toxicity along with altered intracellular calcium homeostasis due to low expression of calci-
um-buffering proteins combined with high expression of α-amino-3-hydroxy-5-methyl-4-isoxazole pro-
pionic acid (AMPA)/kainate receptors lacking the GluR2 (Jaiswal and Keller, 2009; Shaw and Eggett, 
2000). Moreover, high expression of certain proteins, such as mutant SOD1, that may aggregate 
(Ogawa and Furukawa, 2014), can also lead to increased vulnerability to toxicity (Ferraiuolo et al., 
2011; Shaw and Eggett, 2000). Finally, reduced capacity for heat shock response and chaperone ac-
tivity represent key features for MN vulnerability in ALS (Ferraiuolo et al., 2011).  
Recently, Kaplan and collaborators (2014) have identified that matrix metalloproteinase-9 (MMP-9) 
is a determinant of the selective neurodegeneration (Kaplan et al., 2014). The authors demonstrated 
that MMP-9 is expressed selectively by the vulnerable fast MNs whilst triggering ER stress and axonal 
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die-back. This finding provides a basis for considering MMP-9 as a candidate target for novel thera-
peutic approaches to ALS. In addition, studies by Vaz et al (2014) have shown increased levels of 
MMP-9 in response to SOD1 accumulation in NSC-34 mSOD1 model (Vaz et al., 2014).  
The major molecular pathways involved in MN degeneration in ALS are depicted in Figure I.2. and 
the molecular mechanisms that have been described in ALS pathology are further detailed in the next 
section (1.3.1-1.3.9). 
 
Figure I.2. Molecular pathways involved in motoneuron degeneration in ALS. Mutant superoxide dismutase 
1 (mSOD1) accumulation and aggregation promotes the disruption of several mechanisms in motoneurons 
(MNs). Aggregation of mSOD1 leads to oxidative stress due to increased production of reactive oxygen species 
(ROS). mSOD1 also elicits endoplasmic reticulum stress (ER) together with impaired proteasome response. Mito-
chondrial dysfunction is observed ALS due to mSOD1 aggregation inside its intermembrane space leading to 
dysregulated energy production and cytochrome c leading to caspase-1 and -3 activation and the apoptotic sig-
naling pathway. Glutamate accumulation in the extracellular space can induce excitotoxicity with high Ca2+ entry 
which aggravates mitochondrial dysfunction. Impaired axonal transport is also observed with accumulation of neu-
rofilaments which may induce axonal retraction. Although not directly related to mSOD1-mediated motor neuron 
injury, altered RNA metabolism is observed in different ALS models being a transversal mechanism of toxicity in 
motor neurons. Adapted from Pasinelli and Brown (2006). 
1.3.1. Deregulated transcription and RNA processing 
Alterations in RNA processing were first implicated in MN degeneration by Lefebvre and colleagues 
in 1995 by the identification of mutations in survival MN protein or gemin-1 gene (SMN1) as a cause 
for SC muscular atrophy (Lefebvre et al., 1995). This protein has a role in the assembly of small nu-
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clear ribonucleo-proteins, which are important for pre-mRNA splicing (Ferraiuolo et al., 2011). More 
recently, microarray analysis of the transcription profiles in a MN-like cell line (NSC-34) has showed 
alterations in the transcription of genes involved in antioxidant and stress responses, apoptosis, im-
munity and protein degradation, in late-stage disease (Ferraiuolo et al., 2011; Kirby et al., 2005) 
As previously mentioned, TDP-43 and FUS/TLS are nuclear proteins involved in RNA processing 
events such as splicing and transcriptional regulation. Pathogenic inclusions, possibly originating from 
the stress granules, may cause mRNA splicing failure which leads to aberrant protein sequences 
(Colombrita et al., 2011). Also, TDP-43 accumulations may sequester RNAs (and other proteins) 
(Polymenidou et al., 2012; Robberecht and Philips, 2013). In addition, oxidation of mRNA has been 
also identified in ALS patients and transgenic (Tg) mice expressing a variety of fALS-linked SOD1 mu-
tations (Barber and Shaw, 2010). 
Other genes coding proteins involved in RNA-binding and/or processing protein dysfunctions in-
clude TATA-binding protein associated factor 15 (TAF15), Ewing sarcoma breakpoint region 1 
(EWSR1), angiogenin (ANG) and senataxin (SETX) (Robberecht and Philips, 2013). 
1.3.2. Oxidative stress 
Oxidative stress consists in a disruption of the cellular redox signaling that recognizes the occur-
rence of compartmentalized redox circuits, by which reactive oxygen species (ROS) production is in-
creased (Packer and Cadenas, 2007). MNs  are susceptible to ROS damage due to low concentra-
tions of antioxidant enzymes, such as catalase and glutathione peroxidase, high content of easily oxi-
dized substrates and inherent high flux of ROS generated during neurochemical reactions (Carri et al., 
2003). Furthermore, in nervous tissue oxidative stress can be detrimental by several interacting 
mechanisms, including direct damage to crucial molecular species, increase in intracellular free Ca2+ 
and release of excitatory amino acids (Barber et al., 2006). Elevated levels of oxidative stress cause 
structural damage and changes in redox-sensitive signaling. Also, high levels of free radicals can hin-
der normal function of several proteins, lipids and DNA, as observed in samples of  cerebrospinal fluid 
(CSF) of ALS patients and post-mortem tissue from both sALS and fALS cases (Barber and Shaw, 
2010; Ferraiuolo et al., 2011). Chang and colleagues (2008) have also showed that mRNA oxidation is 
present in both ALS patients and mSOD1 mice (Chang et al., 2008). 
The identification of SOD1 mutations as contributors to ALS has revealed a clear association be-
tween oxidative stress and disease onset (Rosen et al., 1993). Indeed, mSOD1 plays an important 
role due to its loss of function in the removal of ROS, however there are studies indicating a gain of 
toxic function that is responsible for the acquisition of the pathological phenotype, rather than an im-
pairment of its anti-oxidant activity (Carri et al., 2003). In addition, not only in neurons but also in mi-
croglia, mSOD1 increases superoxide production by NADPH oxidases (Nox), transmembrane proteins 
capable of reducing oxygen to superoxide (Marden et al., 2007). The increase in its activity can be 
pathogenic and was found to be up-regulated in both sALS patients and SOD1G93A mutant mouse 
model (Marden et al., 2007). Additionally, microarrays studies have shown down-regulation of genes 
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involved in antioxidant response in MNs expressing mSOD1 (Kirby et al., 2005). Nrf2, a transcription 
factor involved in regulating antioxidant response, was reported to have decreased mRNA and protein 
expression in ALS patients (Sarlette et al., 2008), which suggests alterations in signaling cascades 
that may hinder the cell’s ability to fight oxidative stress. 
Multiple studies have implicated oxidative stress with other pathological processes that occur in 
ALS and possibly having a role in their exacerbation. These processes include excitotoxicity, mito-
chondrial damage, protein aggregation and microglial and astrocyte signaling (Barber and Shaw, 
2010; Ferraiuolo et al., 2011). 
1.3.3. Excitotoxicity 
Glutamate is the main excitatory neurotransmitter in the human CNS, acting on both ionotropic and 
metabotropic receptors, the main ionotropic receptor classes being NMDA and α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA)/kainate (Dingledine et al., 1999; Heath and Shaw, 2002).  
Excitotoxicity, which has been reported as an important cause of neuronal death in ALS, is neuronal 
degeneration induced by overstimulation of glutamate receptors and this mechanism can occur when 
extracellular glutamate concentration increases or when the postsynaptic neuron becomes vulnerable 
to normal glutamate levels (Barber and Shaw, 2010; Van Damme et al., 2005). In particular, MNs are 
susceptible to toxicity through activation of AMPA receptors (Shaw, 2005). Additionally, lethal injury to 
neurons, astrocytes or microglia may lead to the release of intracellular glutamate which can result in 
excitotoxicity to the surrounding neurons (Van Damme et al., 2005).  
The excitatory amino acid transporters (EAATs) play a crucial role in the regulation of extracellular 
glutamate concentration, by stimulating the reuptake of glutamate to maintain a physiological concen-
tration in the synaptic cleft. In particular, EAAT2 is the major glutamate transporter and is widely dis-
tributed in the human CNS (Musaro, 2010). It has been reported that EAAT2 is diminished in sporadic 
and familial ALS patients, both in the motor cortex and SC (Rothstein et al., 1992; Van Damme et al., 
2005). This will lead to an excessive glutamate content in the synaptic cleft, which is toxic to neurons. 
This excessive glutamate will result in glutamate-triggered Ca2+ entry, which may come from a subset 
of AMPA/kainate lacking GluR2 AMPA subunit allowing them to become Ca2+-permeable (Rao and 
Weiss, 2004). This permeability of Ca2+ allows its uptake into MN mitochondria increasing ROS gen-
eration, therefore contributing to the oxidative stress and excitotoxicity that ultimately leads to MN de-
generation (Rao and Weiss, 2004; Van Damme et al., 2007). 
1.3.4. Protein aggregation 
Abnormal protein folding and aggregation is a common pathological feature of many neurodegen-
erative diseases, including ALS. Their role in disease pathogenesis, however it is not well defined, as 
they could represent harmless bystanders, or they could be beneficial to the cell by sequestering po-
tentially toxic intracellular proteins (Barber and Shaw, 2010; Shaw, 2005). A variety of protein aggre-
gates has been described in ALS, the most common of which is the ubiquitinated inclusion. Many cy-
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toplasmic aggregates from different proteins were found in fALS cases, such as SOD1, TDP-43 and 
FUS.  
Mutant SOD1 (mSOD1) aggregates are found in fALS Tg mice and in cell culture models (Gurney 
et al., 1994; Vaz et al., 2014) which will contribute to aberrant protein folding and degradation in dis-
ease pathogenesis (Wood et al., 2003). A set of hypotheses for the pathogenesis of ALS is the con-
formational instability of mSOD1 that induces the formation of harmful aggregates (Pasinelli and 
Brown, 2006). Several hypotheses have been put forward to explain how mSOD1 aggregates could 
produce cellular toxicity: (i) there might be by sequestration of other proteins required for normal MN 
function; (ii)  by repeatedly misfolding, the SOD1 aggregates may reduce the availability of chaperone 
proteins required for the folding and function of other essential intracellular proteins; (iii) the SOD1 mu-
tant protein aggregates may reduce the proteasome activity needed for normal protein turnover; (iv) 
there could be an inhibition of the function of specific organelles (e.g. mitochondria) by aggregation on 
or within these organelles (Shaw, 2005). 
TDP-43 is present in neuronal inclusions in most ALS patients (Rutherford et al., 2008; Sreedharan 
et al., 2008). Under normal conditions, TDP-43 is predominantly localized in the nucleus, and loss of 
nuclear TDP-43 staining is seen in most cells containing TDP-43-positive cytoplasmic inclusions 
(Neumann et al., 2006). TDP-43 inclusions are not restricted to MNs, and it seems that cytoplasmic 
redistribution of TDP-43 is an early pathogenic event in ALS. In 2008, mutations in TARDBP, the gene 
encoding TDP-43, were discovered in several fALS pedigrees (Sreedharan et al., 2008). Similarly, 
cytoplasmic inclusions containing mutant fused in sarcoma (FUS) protein have been observed in 
some patients with FUS-related fALS (Hewitt et al., 2010). 
1.3.5. Mitochondrial dysfunction 
Mitochondria plays an essential role in intracellular energy production, calcium homeostasis and 
apoptosis control. This organelle is especially important due to MNs inherent high metabolic demand 
that requires optimal mitochondrial function. These functions, along with other properties of the mito-
chondria are potentially relevant in the pathogenesis of ALS and in other neurodegenerative diseases. 
Indeed, mitochondrial degeneration occurs early in disease onset as a result of mSOD1-caused dys-
function and structural damage in both cultured neuronal cells and Tg mice through unknown mecha-
nisms (Higgins et al., 2003). Evidence for mitochondrial dysfunction include: (i) alterations in the mor-
phology of mitochondria in hepatocytes, muscle, and MNs; (ii) increased mitochondrial volume and 
Ca2+ levels within motor axon terminals in muscle biopsies from sALS cases (Siklos et al., 1996); (iii) 
reduced complex IV activity in spinal motor neurons in sALS (Borthwick et al., 1999); (iv) high fre-
quency of mitochondrial DNA mutations in motor cortex tissue in sALS (Dhaliwal and Grewal, 2000); 
(v) multiple mutations and decreased mitochondrial DNA in muscle and SC in in sALS (Wiedemann et 
al., 2002); (vi) ALS-like phenotype in one patient with a deletion in the cytochrome oxidase c subunit 
gene (Comi et al., 1998). In addition, it was proposed that mSOD1 is imported and accumulates inside 
the mitochondria, which causes direct damage of the organelle and activation of cell death through the 
activation of caspases-1 and -3 (Pasinelli et al., 2004; Pasinelli et al., 2000). Pasinelli and colleagues 
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(2004) have also demonstrated that mSOD1 aggregates interact with the anti-apoptotic protein Bcl-2 
both in vitro and in vivo mouse models and human SCs (Pasinelli et al., 2004). This binding can con-
sequently lead to the entrapment of Bcl-2 and rendered nonfunctional as the mSDO1 protein aggre-
gates, thus facilitating triggering of apoptosis (Pasinelli et al., 2004). 
Mitochondrial dysfunction has been offered as a converging point for the multiple pathways that 
cause apoptosis activation and neuronal loss in ALS. The role of disturbance in the mitochondrial 
function and transport in the pathogenesis of ALS has been revealed using mSOD1 mice as a familial 
model of ALS (Bendotti and Carri, 2004). The cause of mitochondrial malfunction may be linked to the 
accumulation of aggregated misfolded proteins such as SOD1 and TDP-43. These aggregates form in 
the ubiquitin-containing inclusions in cell bodies and axons of MNs. Notably, SOD1 is basically a cyto-
solic protein but it partly deposits in the intermembrane spaces of mitochondria in mSOD1 mice 
(Higgins et al., 2003), a fact that can explain its harmful effect on the mitochondrial function. 
1.3.6. Endoplasmic reticulum stress 
The endoplasmic reticulum (ER) functions as the site of translation, folding and transport of mem-
brane proteins and secreted proteins, along with Ca2+ storage and has a role in lipid synthesis. The 
presence of misfolded proteins or protein aggregates triggers a defense mechanism called unfolded 
protein degradation (UPR) through ER-resident chaperones (Matus et al., 2013). The presence of 
these non-functional proteins can lead to translation and ER-association protein degradation suppres-
sion, however, if not stopped, these mechanisms can lead to the activation of apoptotic signaling 
(Ferraiuolo et al., 2011). mSOD1 aggregates were found to accumulate in ER membranes binding to 
the ER-luminal polypeptide chain binding protein (BiP) in affected tissues in a progressively negative 
manner (Ilieva et al., 2009; Kikuchi et al., 2006), a chaperone that regulates the activation of ER 
transducers such as inositol-requiring kinase 1 (IRE1), PKR-like endoplasmic reticulum kinase (PERK) 
and activating transcription factor 6 (ATF6). 
Furthermore, ER has been implicated in the pathology of ALS at early stages of the disease where 
a marker of protein disulphide isomerase (PDI), a chaperone and a marker of the UPR, was found to 
co-localize with mSOD1 inclusions in Tg mice, and also in biosamples from patients with sALS. Mark-
ers of ER stress were also found to be upregulated in the CSF and SC of sALS patients (Atkin et al., 
2006; Atkin et al., 2008). 
1.3.7. Deregulated endosomal trafficking 
Endocytosis is the process by which cells perform the uptake of extracellular molecules into their 
cytoplasm through vesicles or vacuoles that will fuse with early endosomes (Cooper and Hausman, 
2004). The cargo is conducted to its destination via the endosomal network. This system has been 
implicated in several subtypes of ALS. Specifically, in the subtype ALS2/ALSIN, a rare autosomal re-
cessive with a juvenile onset, alsin is a guanine nucleotide exchange factor (GEF) acting to promote 
neurite outgrowth (Hadano et al., 2001). In cultured MNs, alsin protects MNs from mSOD1-mediated 
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toxicity which infers to a possible neuroprotective role (Kanekura et al., 2004). Mutations in alsin cause 
disruption of the endolysomal system, leading to an aggregation of immature vesicles and misfolded 
proteins in neurons (Chen et al., 2013; Ferraiuolo et al., 2011). Other ALS-associated mutations sug-
gest dysregulated endosomal trafficking as pathophysiological mechanism in ALS. These include mu-
tations in the vesicle associated membrane protein-associated protein B (VAPB), optineurin, a com-
ponent of the endosomal sorting complex required for transport (ESCRTIII), charged multivesicular 
protein 2B (CHMP2B), VCP which forms a complex with the endocytotic protein clathrin, and Sac do-
main-containing protein gene family (FIG4) a phosphoinositide 5-phosphatase (PI(3,5)P2 which is in-
volved in helping the retrograde trafficking of endosomal vesicles to the trans-Golgi network (Chen et 
al., 2013; Ferraiuolo et al., 2011). Recently, Farg and colleagues (2014) have reported C9ORF72 has 
being implicated in the regulation of endosomal trafficking. This study reveals that the C9ORF72 co-
localizes with Rab proteins in neuronal cell lines and human SC, consistent with the suspicion of a 
RabGEF activity for C9ORF72 (Farg et al., 2014). 
1.3.8. Impaired axonal transport 
MNs are characterized by having long axonal processes necessary for conduction of electrical im-
pulses and transport of essential constituents (e.g. RNA, organelles and proteins), to and from the 
synaptic structures to the cell body. This transport involves two main molecular motors: microtubule-
dependent kinesin, which mediates transport from the soma to the neuromuscular junction (NMJ) (an-
terograde transport) and dynein towards the cell body (retrograde transport). This system is set upon a 
neuronal intermediate filament network, composed mainly by neurofilaments (NFs), that is responsible 
for cell shape and axonal caliber maintenance. Dysfunction in the axonal transport is characteristic of 
the pathology of ALS as the incorrect assembly of neurofilaments due to over- or under-expression, 
mutation or deficient transport of individual subunits causes them to accumulate, both in human and 
mouse models (Redler and Dokholyan, 2012). mSOD1, contrary to wild-type SOD1, is reported to bind 
to the 3’ un-translated region of neurofilament-light subunits (NF-L) mRNA increasing  mRNA instabil-
ity and degradation (Ge et al., 2005). Axonal transport dysfunction may also be a consequence of oth-
er pathogenic mechanisms involved in ALS, such as mitochondrial impairment which can lead to insuf-
ficient energy required for the energy-dependent transport mechanism. In mSOD1 mice, tumor necro-
sis factor (TNF) is elevated which causes disruption of kinesin function via a mechanism involving p38 
mitogen-activated protein kinase (p38 MAPK), a stress-activated protein that can phosphorylate 
NFG/NFM (Ackerley et al., 2004). Hyperphosphorylation of neurofilaments contributes to defective 
transport by causing their detachment from motor complexes and promoting aberrant self-association 
(Redler and Dokholyan, 2012). Also, pro-inflammatory cytokines lead to activation of p38, and p38 
activity is shown to be elevated in SCs of mSOD1 mice (Ackerley et al., 2004; Hu et al., 2003). Re-
cently, Alami and collaborators (2014), implicate a role for TDP-43 in the cytoplasm of MNs cells sup-
porting anterograde axonal transport of target mRNAs from the cell body to axonal compartments. 
Therefore, mutations in TDP-43 induce partial loss of function and can cause deficient axonal 
transport of mRNA targeted by TDP-43 (Alami et al., 2014). Interestingly, ALS has been described as 
a “dying-back axonopathy” due to the progression of defects from distal to proximal with probable con-
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tribution from abnormalities in anterograde transport and mitochondrial dysfunction (Ferraiuolo et al., 
2011; Fischer et al., 2004).  
1.3.9. Cell death 
There are several mechanisms of cell death that may be implicated in MN degeneration in ALS and 
apoptosis seems to be the most common mechanism by which these cells die (Guegan and 
Przedborski, 2003). As reviewed by Ghavami et al. (2014), apoptosis is a mechanism of programmed 
cell death in which biochemical events lead to characteristic cellular changes and ingestion by phago-
cytes. The main molecular components of the apoptotic mechanism include the Bcl-2 family of onco-
proteins, caspase family of proteolytic enzymes and the apoptosis inhibitor family of proteins (Guegan 
and Przedborski, 2003). Caspase activation can be triggered by three main pathways: release of pro-
apoptotic factors (e.g. cytochrome c released from mitochondria); activation of cell surface ligand re-
ceptor systems of the tumor necrosis factor family including Fas-Fas ligand, with subsequent recruit-
ment of cytosolic adaptor proteins; and stress to the endoplasmic reticulum with activation of caspase-
12 (Shaw, 2005). 
Evidence that MNs die in ALS by programmed cell death include evidence of structural morphology 
of degenerating MNs compatible with apoptosis (Guegan and Przedborski, 2003). Studies in in vitro 
cultures, rodent models and post-mortem human spinal cord demonstrate that mSOD1 aggregates 
can bind to Bcl-2 proteins in a manner that the anti-apoptotic function of the protein in cancelled, thus 
promoting an imbalance of the Bcl-2 family of proteins towards apoptosis (Pasinelli et al., 2004). In 
addition, increased activation of the initiator caspase-9 was reported, as well as an increase in the ac-
tivity of caspases-1 and -3 in MNs and astrocytes in ALS mice (Li et al., 2000; Pasinelli et al., 2000; 
Vaz et al., 2014; Yoshihara et al., 2002). 
While activation of apoptotic pathways have long been implicated in the demise of MNs in ALS, it is 
becoming increasingly clearer that apoptosis is not the only cellular mechanism that regulates cell 
death in this pathology. Recently, a relatively new form of necrosis has been characterized as necrop-
tosis (Wu et al., 2012), which is biochemically regulated and requires the involvement of receptor in-
teraction protein kinase 1 and 3 (RIP1 and RIP3). Interestingly, Re et al. (2014) showed that in the 
absence of caspases activation, MN demise triggered by sALS as well as fALS astrocytes might in-
volve necroptosis, a specialized form of necrotic cell death that involves the activation of the kinase 
domain of RIP1 and subsequent recruitment of a mixed lineage kinase domain-like protein (MLKL). 
Another cell death mechanism that deserves our attention is autophagy. Autophagy plays a pivotal 
role in keeping the cell homeostasis by digestion of dysfunctional organelles and proteins (Chen et al., 
2012). High levels of aggregated proteins can cause UPS dysfunction and subsequently, compensato-
ry activation of autophagy (Korolchuk et al., 2010). In the recent years, defective autophagy pathway 
or alterations in autophagy-related genes has been shown in various human pathologies such as neu-
rodegenerative diseases (Ghavami et al., 2014). For instance,  post-mortem studies, as well as animal 
models, have demonstrated that the number of autophagosomes is increased in ALS SCs (Kim et al., 
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2013). In addition, Pizzasegola and collaborators (2009) have reported that treatment with lithium, 
which activates autophagy, exacerbates disease progression in ALS (Pizzasegola et al., 2009). An-
other study with rapamycin, which is also an inducer of autophagy, aggravates disease progression in 
ALS mice (Zhang et al., 2011). However, studies using lithium and rapamycin have shown the oppo-
site effects thus leaving the precise role of autophagy in ALS unsettled (Fornai et al., 2008; Wang et 
al., 2012a) 
2. ALS is a non-cell autonomous disease: the importance of glial cells 
Studies of mutant SOD1 mice have shown that cell death in ALS is non-cell autonomous, as astro-
cytes and microglial cells that surround motor neurons may contribute to disease onset and/or pro-
gression (Figure I.3) (Clement et al., 2003; Evans et al., 2013). Indeed, it is described that glial cells, 
namely astrocytes and microglia, become increasingly activated as the disease progresses in both 
animal models and patients (Gurney et al., 1994). Expression of the mSOD1 protein in microglia is 
sufficient to cause cellular toxicity to the neurons, resulting in neuronal degeneration. This has been 
shown using both cell culture and in vivo experiments, and illustrates the importance of both astro-
cytes and microglia in ALS (Evans et al., 2013). In addition, Clement and colleagues (2003), by using 
chimeric mice, demonstrated that the toxicity to MNs requires non-neuronal cells expressing mSOD1, 
as shown by the fact that mSOD1 MNs surrounded by healthy microglia and astrocytes presented de-
layed degeneration and prolonged survival, whereas the reverse (healthy MNs surrounded by 
mSOD1-overexpressing microglia) shows the development of the pathology (Clement et al., 2003). In 
addition, several studies with different approaches have demonstrated that mutant SOD1 expression 
in MNs determines the initial timing of disease onset and early progression in some cases, but does 
not have a significant contribution to later disease progression (Ilieva et al., 2009). Consequently, as-
trocytes and microglia must have decisive implications in disease progression after its onset. It is also 
important to mention that, mutant SOD1 gene excision from microglia and selective reduction in astro-
cytes significantly slowed disease progression (Boillee et al., 2006a). In addition to astrocytes and mi-
croglia, oligodendrocytes may also have a role in ALS. In fact, it was recently reported the loss of the 
monocarboxylate transporter 1 (MCT1) in both ALS patients and mSOD1 transgenic mice (Lee et al., 
2012b) together with the identification of an apoptotic oligodendrocyte phenotype in the ventral grey 
matter of the SC from mSOD1 transgenic mice prior to the actual MN loss became evident (Valori et 
al., 2014). 
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Figure I.3. ALS is a non-autonomous cell disease. Motoneuron (MN) degeneration is dependent on glial cell, 
microglia has increased proliferative and phagocytic abilities whilst having increased production reactive oxygen 
species (ROS) and nitric oxide (NO) as well as inflammatory molecules like tumor necrosis factor α (TNF-α) and 
interleukin 1β (IL-1β). Astrocytes have been shown to have downregulation of excitatory aminoacid transporter 2 
(EAAT2) high expression of glial fibrillary acidic protein (GFAP) from activation. Furthermore, astrocytes have 
increased generation of pro-inflammatory cytokines along with ROS and NO. Oligodendrocytes have been report-
ed having loss of monocarboxylate transporter 1 (MCT1) thus contributing to ALS progression. Schwann cells 
involvement in ALS is controversial, however some studies show increased myelin abnormalities in presympto-
matic mSOD1 mice. Adapted from Ilieva (2009). 
2.1. Oligodendrocytes and Schwann cells 
Oligodendrocytes are essential cells for the normal function of the CNS. They play a pivotal role in 
axonal maintenance by providing myelin sheaths for rapid signal conduction (Valori et al., 2014). As 
previously mentioned, ALS is characterized by axonal loss and neuronal atrophy which may be asso-
ciated with an important role of oligodendrocytes due to its myelinating function (Lasiene and 
Yamanaka, 2011). Indeed, recent studies report abnormalities in these cells in post-mortem ALS pa-
tient’s SC and mouse models. Studies in ALS SOD1G93A mice reveal an increase of proliferation rate 
of oligodendrocyte precursor (NG2) cells (Kang et al., 2013), a class of progenitor cells that have the 
capacity to differentiate into oligodendrocytes. Oligodendrocytes normally express MCT1 which pro-
vides neurons with lactate, and studies in in vitro using neuroblastoma 2a cells as well as mSOD1 in 
vivo models have shown that the expression of this transporter is reduced, and this loss is toxic to 
MNs (Philips et al., 2013). In a study by Phillips and collaborators (2013) they investigated oligoden-
drocytes and NG2 cells and found that oligodendrocyte lineage cells may be targets of disease in both 
human patients with ALS and mSOD1 mice. In SOD1G93A mice, oligodendrocytes showed signs of 
degeneration and death before MN loss together with upregulation of caspase-3 (Philips et al., 2013). 
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Another evidence for the potential involvement of oligodendrocytes in ALS is the discovery of a dis-
ruption of gap junctions, focusing on the study of connexins (Cx) 32 and 47 expressed by these cells. 
Cui et al. (2014) demonstrated that the levels of oligodendrocytic Cx47 and Cx32 are markedly dimin-
ished in the anterior horns of SCs from SOD1G93A mice, suggesting that disruption of the glial syncyt-
ium due to alteration of connexin expression might contribute to the progression of MN disease (Cui et 
al., 2014). 
Another evidence for the potential involvement of oligodendrocytes in ALS is the aberrant location 
of TDP-43 to the cytoplasm rather than the nucleus, which is a morphological hallmark of patients with 
sALS (as previously addressed in 1.3.4), is not limited to MNs, but also occurs in oligodendrocytes 
(Seilhean et al., 2009). 
In the peripheral nervous system the role of myelination is performed by Schwann cells (Morrison 
et al., 2013). The involvement of Schwann cells in ALS pathology is still poorly understood. However, 
studies using G37R mice with mSOD1 knockdown in Schwann cells show aggravated disease pro-
gression (Lobsiger et al., 2009). On the other hand, Wang et. al have shown that the selective knock-
down of mSOD1 in Schwann cells mitigates disease progression using G85R mice  (Wang et al., 
2012b). These results suggest that different mutations can have different impacts on cellular toxicity 
and disease progression. 
2.2. Astrocytes 
Astrocytes comprise about 85% of all glial cells, and contribute to the maintenance of vascular, ion-
ic, redox and metabolic homeostasis in the brain (Allen and Barres, 2005). They fulfill a structural role 
along with maintenance of the homeostasis of the extracellular environment, influencing neuronal ex-
citability by regulating the levels of ions and neurotransmitters, more specifically the uptake of gluta-
mate from the synaptic cleft and nourish motoneurons through the release of neurotrophic factors 
(Evans et al., 2013; Philips and Robberecht, 2011). It has being proposed that a hallmark of the path-
ophysiology of ALS is the reactive astroglyosis as a response to brain injury, which is accompanied by 
a characteristic up-regulation of the intermediate filament glial fibrillary acidic protein (GFAP), an as-
trocytic marker, as well as the marker aldehyde dehydrogenase 1 family, member L1 (ALDH1L1) 
(Evans et al., 2013; Philips and Robberecht, 2011). More recently, Diaz-Amarilla et al. (2011) have 
identified a population of phenotypically aberrant astrocytes in which there is a decrease of the GLT-
1/EAAT2 transporter, thus impairing glutamate clearance, as previously addressed in point 1.3.3. of 
this section (Yamanaka et al., 2008), as well as increased expression of S100B and connexin 43 
(Cx43). In this model, aberrant astrocytes from transgenic SOD1G93A rats produced soluble factors 
that were bound to be toxic to co-cultured MNs. One of the pathways by which astrocytes may induce 
MN toxicity is through the up-regulation of NADPH oxidase 2 (NOX2) to produce superoxide, since the 
NOX2 inhibitor, apocynin, was demonstrated to prevent motor neuron loss caused by mSOD1 astro-
cytes (Zhao et al., 2013a). In addition, models of ALS using mSOD1G93A rats showed that astrocytes 
induce up-regulation of the glutamate receptor subunit GluR2 in neighboring (co-cultured) MNs. The 
GluR2 subunit produces receptors that are impermeable to Ca2+, thereby protecting the MNs from ex-
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citotoxic damage (Ilieva et al., 2009). Indeed, it was shown that mSOD1 expression in astrocytes ab-
rogated their GluR2-regulating capacity, rendering MNs vulnerable to excitotoxicity (Van Damme et 
al., 2007). Astrocytes are also able to modulate neuronal integrity through the release of neurotrophic 
factors, of which glial-cell derived neurotrophic factor (GDNF), brain-derived neurotrophic factor 
(BDNF), insulin-like growth factor 1 (IGF1) and vascular endothelial growth factor (VEGF) are well 
studied examples (Ekestern, 2004). Interestingly, exogenous administration of these factors increases 
survival of MNs in the mSOD1 model which appear to be related to a disruption of the release of neu-
rotrophic factors (Philips and Robberecht, 2011). One other molecule that deserves our attention is the 
nuclear factor erythroid-2-related transcription factor 2 (Nrf2). Activation of Nrf2 in astrocytes is 
thought to coordinate the up-regulation of antioxidant defenses, thereby conferring protection to 
neighboring neurons (Vargas et al., 2008). Indeed, astrocyte-selective up-regulation of Nrf2 produced 
significant delay in disease onset in mouse models overexpressing dismutase-active and –inactive 
SOD1 mutants (Lasiene and Yamanaka, 2011; Vargas et al., 2008). On the other hand, astrocytes 
release the glutathione precursor (CysGly), which is used by MNs to synthesize the antioxidant gluta-
thione to provide significant protection against oxidative stress (Zhao et al., 2013a). Direct evidence of 
altered glutathione or glutathione utilizing enzymes levels in sporadic and familial ALS remain contro-
versial as some studies in post-mortem brain samples from ALS patients (Przedborski et al., 1996a), 
and in blood samples from ALS patients (Przedborski et al., 1996b) observed reduced glutathione pe-
roxidase activity while others do not detect changes in activity (Fujita et al., 1996). Astrocytes can also 
help suppress cytotoxic microglial activation by releasing Transforming growth factor-β (TGF-β), whilst 
M1 microglial release of IL-1β can promote astrocytic activation (Liu et al., 2011). Finally, the role of 
astrocytes in the maintenance of CNS homeostasis may be compromised due to Cx expression 
dysregulation, namely, Cxs 43 and 30, which were found to be overexpressed in both SOD1G93A 
mice model and cell cultures obtained from adult spinal cord of symptomatic SOD1G93A rats (Cui et 
al., 2014; Diaz-Amarilla et al., 2011). 
2.3. Microglia 
Microglia are cells derived from the hematopoietic cell lineage and are considered the primary im-
mune cells of the CNS. Microglia are the resident macrophages of the CNS, and have two distinct 
roles: first they have a supporting role to neurons in conjunction with astrocytes and they have an im-
munological role, which may have cytotoxic properties. Under physiological conditions microglia are in 
a state called “resting microglia” in which surveys the surrounding environment through its processes 
in order to sense insults such as abnormal proteins produced in neurodegenerative diseases (Graeber 
and Streit, 2010).  
Microgliosis has been proposed as a main feature of ALS pathology, as well as neuroinflammation, 
where microglia certainly plays a key role (Moisse and Strong, 2006). In fact, there is a marked activa-
tion microglia in the brain of living ALS patients detectable by positron emission tomography (PET) 
(Turner et al., 2004). The role of microglia in neuroinflammation in ALS will be further detailed in the 
following chapter. 
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3. Neuroinflammation in ALS: the role of microglia 
Neuroinflammation is a hallmark of ALS pathology and is characterized by gliosis and the accumu-
lation of an increased number of activated microglia and astrocytes, in both ALS patients and mouse 
models (Evans et al., 2013; Turner et al., 2004). Markers for such glial cells have been found to be 
altered in ALS patients, namely, the increased expression of astrocytic marker glial fibrillary acidic pro-
tein (GFAP) (Kawamata et al., 1992), together with higher expression of leukocyte common antigen 
(LCA), lymphocyte function associated molecule-1 (LFA-1) and complement receptors CR3 (CD11b) 
and CR4 (CD11c) suggesting increased microglial immune activity (Phani et al., 2012). These last 
markers suggest an activation of microglia and macrophages in ALS affected regions such as the mo-
tor cortex, brainstem and corticospinal tract (Kawamata et al., 1992; Papadimitriou et al., 2010). Other 
studies reveal immunological differences between the blood of ALS patients and healthy controls such 
as increased levels of cluster of differentiation (CD4+) cells and reduced CD8+ T-lymphocytes (Phani 
et al., 2012). In addition, there is a marked decrease in expression of CD4+CD25+ T-regulatory cells 
and CD14+ monocytes (Mantovani et al., 2009). Analysis of CSF of ALS patients show a dysregula-
tion in pro- and anti-inflammatory cytokines such as IL-1β, TNF-α, Interferon- γ (INF-γ), IL-6 and IL-10, 
along with altered levels of growth factors like VEGF (Evans et al., 2013; Ghavami et al., 2014; 
McGeer and McGeer, 2002). 
As previously mentioned, the pathogenesis of ALS is non-cell autonomous disease, which means 
that the MN degeneration requires the participation of non-neuronal cells. This concept is particularly 
important for the role of the immune system in the pathological progression of the disease. Microglia 
play a pivotal role in neuroinflammation as they act as the first line of immune defense in the CNS and 
respond to “danger signals” released from the damaged tissue. 
3.1. Microglia phenotypes: neuroprotection vs. neurotoxicity 
In physiological conditions, microglia in the CNS is most of the time in a state called “resting micro-
glia” (Li et al., 2013a) characterized by its thin, highly branched processes emerging from the cell body 
which survey the environment for potential threats (Luo and Chen, 2012). In response to insults such 
as microbial infection, serum microhemorrage of blood vessels, immunoglobulin-antigen complexes 
and abnormal protein produced in neurodegenerative diseases (e.g. mSOD1), microglia contributes to 
the neuroinflammatory process acquiring rapid morphological and functional activation which includes 
phagocytosis, antigen presentation, as well as the production and secretion of ROS, cytokines and 
growth factors (Evans et al., 2013; Lasiene and Yamanaka, 2011). These insults can be exogenous or 
endogenous, the latter including cytokines and chemokines, including IFN-γ, TNF-α, IL-1β and IL-6 
(Dewil et al., 2007). Cumulative studies using diverse animal models of CNS injury have demonstrated 
that microglia have very distinct and different phenotypic states, as schematically represented by Fig-
ure I.4., and, in line with other tissue macrophage populations, they may exert either a neurotoxic or 
neuroprotective response depending on the physiological conditions they encounter. These states are 
classified as classically activated microglia (M1), which are cytotoxic due to the secretion of ROS, pro-
inflammatory cytokines, and increased levels of NOX2 expression (Liao et al., 2012), and this pheno-
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type is influenced by T helper cell type 1 (Th1) that release GM-CSF and INF- γ, thus triggering M1 
proliferation (Brites and Vaz, 2014). In contrast, alternatively activated microglia (M2) can be promoted 
by IL-4 and IL-13 (Olah et al., 2011). This phenotype promotes neuroprotection by blocking the pro-
inflammatory response and producing high levels of anti-inflammatory cytokines and neurotrophic fac-
tors (Evans et al., 2013; Henkel et al., 2009; Liao et al., 2012). This M2 phenotype can be divided into 
three sub-phenotypes: the M2a or alternate activation repair/regeneration/remodeling phenotype, the 
M2b immunoregulatory and the M2c acquired-deactivating as reviewed in Brites (2014). Markers for 
M2a include arginase (Arg1) and mannose receptor and IGF-1 (Varnum and Ikezu, 2012). M2b is 
stimulated by immune complexes, TLR agonists and IL-1R ligands and useful markers are interleukin-
1 receptor antagonist (IL-1Ra) and suppressor of cytokine signaling 3 (SOCS3) (Chhor et al., 2013). 
Characterization of M2c stimulated by IL-10, transforming growth factor-β (TGF-β) and glucocorticoids 
is obtained through the increased levels of anti-inflammatory cytokines (IL-10,TGF-β), low levels of 
pro-inflammatory cytokines and enhanced IL-4Rα, Arg1, (SOCS3), and CD206 (Varnum and Ikezu, 
2012). M1 and M2c phenotypes are proposed as being those capable of expressing and releasing 
MFG-E8 for phagocytic purposes (Brites and Vaz, 2014). 
Recently, Liao and collaborators (2012) have demonstrated that there are both states of activated 
microglia over the course of disease and indicate that early in the disease process, mSOD1 microglia 
expressed more M2 related mRNAs, such as Ym1 and CD206, when compared with near end-stage 
mSOD1 microglia as the near end-stage microglia expressed more M1 markers, namely NOX2. A 
transition between states of activation suggests that earlier in disease, M2 microglia mainly has a role 
of neuroprotection and then undergo into a phenotypically transformation to a more neurotoxic M1 mi-
croglia. In addition, it was reported in the same study that, at early stages, the neuroprotection from 
M2 mSOD1 microglia is enhanced by astroglia leading to MN protection, while during disease pro-
gression it seems to be a transformation of mSOD1 microglia from a neuroprotective M2 phenotype to 
a cytotoxic M1 phenotype (Liao et al., 2012). 
 
Figure I.4. Microglia phenotype diversity. Surveiling microglia changes phenotype in response to various 
stimuli. Classical activation phenotype (M1), characterized as having a neurotoxic response, is induced by Tumor 
Necrosis Factor α (TNF-α), Interleukin (IL) -1β and -12 and Nitric Oxide (NO). Alternative activation (M2), charac-
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terized as having a neuroprotective response, is induced by IL-4, IL-13 and IL-10. M2 phenotype can be further 
divided into three sub-phenotypes: M2a repair/regeneration/remodeling phenotype, expressing Insulin-like growth 
factor 1 (IGF-1) and arginase (Arg1) markers; M2b immunoregulatory phenotype expressing interleukin-1 receptor 
antagonist (IL-1Ra) and suppressor of cytokine signaling 3 (SOCS3); M2c acquired-deactivating phenotype which 
is stimulated by IL-10 and Transforming growth factor-β (TGF- β). 
3.2. Neuron-microglia dialogue in ALS 
Communication between neurons and glial cells is essential for the maintenance of the CNS. Neu-
rons are highly active and vulnerable cells that require microglial support. Microglia can release factors 
such as IGF-1 and BDNF (Olah et al., 2011). In addition, peripheral nerve damage specifically acti-
vates microglia in the CNS at the corresponding innervation site of the injured nerve, which indicates a 
directed communication between damaged neurons and microglia (Biber et al., 2007).  
Chemokines are also able to induce a chemotactic cellular response. Chemokines are classified in-
to four main subfamilies: CXC, CC, C and CX3C. Most of the members of all these families (except for 
C chemokines) have been described in neurons and for most of them microglia express the corre-
sponding receptors and respond in vitro by having an increased chemotaxis (Biber et al., 2008). 
Chemokine (C-X3-C motif) ligand 1 (CX3CL1), or fractalkine, was found in neurons to have a role in 
specific communication with microglia, which are the only cells in the CNS that expresses the corre-
spondent receptor CX3C chemokine receptor 1 (CX3CR1) (Harrison et al., 1998). MNs have been 
documented to promote microglia-mediated neuroprotection through CX3CL1-CX3CR1 signaling. In 
vivo, CX3CR1 deficiency deregulates microglial response, resulting in neurotoxicity (Cardona et al., 
2006). Also, Tg mSOD1/CX3CR1-/- mice exhibited more extensive neuronal cell loss than CX3CR1lps 
littermate controls. Thus, CX3CL1 release from MNs enhances neuroprotection, and the loss of 
CX3CR1 on microglia promotes neurotoxicity. Another report indicates that CX3CL1 treatment of cul-
tured microglia increases milk fat globule factor-E8 (MFG-E8) mRNA levels, thus promoting phagocy-
tosis of neurons by microglia (Leonardi-Essmann et al., 2005). CX3CL1 is a membrane-bound protein 
that is cleaved to its soluble form following cell stress or injury, which then acts as a chemoattractant 
for T cells, monocytes and microglia (Fuller and Van Eldik, 2008). Another relevant chemokine is 
CCL21, which was shown to be implicated in signaling neuronal injury to microglia through the recep-
tor CXCR3. This chemokine appears to have be a chemotactic agent release by damaged neurons 
and is important to drive microglia to the site of lesion (de Jong et al., 2005). These authors ascertain 
that CCL21 is transported within vesicles that are transported along the neuronal process towards 
presynaptic structures. Astrocytes also exhibited the receptor CXCR3 but do not reveal significant al-
terations unless high levels of CCL21 are produced (van Weering et al., 2010). Curiously, the 
CCL21/CXCR3 signaling axis was never explored in the context of ALS. 
As previously mentioned, one of the roles of alternatively activated microglia is phagocytosis. 
Through this process, MFG-E8 produced by microglia recognizes phosphatidylserine (PS) as a “eat 
me” signal that is expressed on the surface of apoptotic neurons, thus triggering the phagocytic mech-
anism (Fuller and Van Eldik, 2008). Leonardi-Essmann and collaborators proved using cultured rat 
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microglia that the up-regulation of CX3CL1 also leads to an increase in MFG-E8 expression (Leonardi-
Essmann et al., 2005) suggesting a combined effort in injury response. Importantly, astrocytes can 
also produce MFG-E8 in order to provide additional support to microglial phagocytic functions (Kranich 
et al., 2010). 
In the same manner, CD200, a member of the immunoglobulin superfamily, is constitutively ex-
pressed at the neuronal membrane surface, and its receptor CD200R is primarily present on microglia 
(Biber et al., 2007). Mice deficient for CD200, a neuronal glycoprotein whose receptor, CD200R, is 
expressed by all myeloid cells, show aberrant microglial physiology including morphological activation 
of microglia in the resting CNS and accelerated response to facial nerve transection (Hoek et al., 
2000). In fact, there are studies showing that WT microglia, after LPS activation, is less neurotoxic 
than mSOD1 microglia due to the enhanced release of neurotrophic factors, such as IGF-1, and at-
tenuated release of free radicals and proinflammatory cytokines (Beers et al., 2006; Xiao et al., 2007). 
Additionally, in microglia-MN co-cultures, treatment with IL-4 suppressed M1 microglial activation pro-
moting an M2 phenotype, reduced release of ROS, enhanced IGF-1 secretion, and improved MN sur-
vival (Zhao et al., 2006). 
CD14 is a pattern recognition receptor for misfolded proteins, which is very important in ALS since 
it is described by Zhao and colleagues (2010) to bind mSOD1, and that the microglial activation medi-
ated by mSOD1 can be attenuated using TLR2, TLR4 and CD14 blocking antibodies in SOD1G93A 
mice model (Zhao et al., 2010). Furthermore, Appel et al. (2011) also demonstrated that mSOD1G93A 
binds to CD14 and its blockade leads to diminished proinflammatory cytokines and increased IGF-1 
released from mSOD1G93A-treated microglia (Appel et al., 2011). As mentioned above in 1.3.4 of this 
introduction, there can also be protein inclusions of TDP43 which was demonstrated by Zhao and col-
leagues (2013) to interact with the CD14 receptor inducing microglial cytotoxic activation and the 
NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome (Zhao et al., 2013b). 
TLR2 and TLR4 are co-receptors for CD14 and previous studies suggested that CD14 and TLR con-
tribute to the inflammatory responses initiated by microglia (Olson and Miller, 2004; Zhao et al., 2010). 
Another microglial receptor involved in triggering inflammatory response is the receptor for advanced 
glycation end products (RAGE), which can function also as receptor for high mobility group box 1 
(HMGB1). HMGB1 is an alarmin that binds to DNA and capable of exerting both extra-nuclear and 
extra-cellular functions. It can be released by dying neurons (Scaffidi et al., 2002). Within the cell it 
acts as a transcription factor, whilst outside it behaves as a cytokine which can lead to a positive feed-
back loop potentiating the secretion of more HMGB1 and can bind to RAGE, TLR2 and TLR4, thus 
generating an inflammatory response (Casula et al., 2011; Muller et al., 2004). Activation of these 
pathways can also lead to the activation of NFκB resulting in production of inflammatory cytokines and 
angiogenic factors (van Beijnum et al., 2008). Casula and colleagues found increased expression of 
TLR2, TLR4 and RAGE concomitant with higher expression of HMGB1 mRNA levels using post-
mortem spinal cord samples obtained from ALS patients indicating an increased inflammatory state in 
late stage disease (Casula et al., 2011). 
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Autotaxin (ATX) functions as a secreted lysophospholipase D that converts lysophosphatidylcho-
line (LPC) to lysophosphatidic acid (LPA), which is involved in a wide array of processes namely, neu-
ral development and the stimulation of cell migration, proliferation and survival of various cells, namely 
microglia (Perrakis and Moolenaar, 2014). LPA receptors are expressed by microglia, astrocytes and 
oligodendrocytes (Hoelzinger et al., 2008). Most importantly, ATX secretion by microglial cells was 
shown to be stimulated by oxidative stress, and that ATX overexpression reduces microglial ROS-
mediated damage and microglial activation (Awada et al., 2012).  
Chromogranins, which are components of neurosecretory vesicles, were documented to interact 
with mutant forms of SOD1 (Urushitani et al., 2006). Mutant SOD1 was also found in immune-isolated 
trans-Golgi network and in some preparations, suggesting that it could be secreted, furthermore, 
chromogranins were demonstrated to act as chaperone-like proteins and promote secretion of SOD1 
mutant proteins (Appel et al., 2011). In fact, since SOD1 is a cytosolic protein that lacks a signal pep-
tide, there must be an alternative mechanism for the extracellular export of this protein. Hence, neu-
ronal ability to produce and release exosomes has drawn attention. Exosomes are small lipid mem-
brane vesicles that formed by fusion of multivesicular bodies with plasma membrane and the subse-
quent release of their cargo. They are important for a variety of pathways, and one of the biological 
functions of exosomal release is the secretion of membrane proteins meant to be discarded or to be 
passed onto other cells (Fruhbeis et al., 2012). These exosomes are characterized by the presence of 
nucleic acids, including mRNAs and miRNAs. Microglia can release exosomes containing IL-1β 
(Bianco et al., 2009) and was shown to internalize oligodendroglial exosomes, with apparent inhibitory 
function of membrane expansion and myelin formation, by micropinocytosis (Bakhti et al., 2011; 
Fitzner et al., 2011). Gomes and collaborators (2007) describe SOD1 secretion in NSC-34 cells asso-
ciated with exosomes (Gomes et al., 2007). This evidence suggests a new cellular mechanism con-
tributing for dissemination of mSOD1 toxicity in ALS pathogenesis. Figure I.5 summarizes major 
communication pathways between MN and microglia. 
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Figure I.5. Dialogue between microglia and motor neurons. Activation of microglia in ALS can be mediated by 
the release of mutant SOD1 (mSOD1) by motor neurons (MNs) through a chromogranin chaperone-like process. 
mSOD1 is recognized by toll-like receptors (TLRs), stimulating an inflammatory response. HMGB1 can be re-
leased from MNs and is recognized by TLRs and the receptor for advanced glycation end products (RAGE). Re-
active oxygen species (ROS) and TLR activation lead to inflammasome activation through the formation of NOD-
like receptor family, pyrin domain containing 3 (NLRP3) and Pro-caspase-1 which then converts Pro-IL-1β and 
Pro-IL-18 into their active forms. Chemokine (C-C motif) ligand 21 (CCL21) can be secreted by MNs and act upon 
microglial chemokine (C-X-C motif) receptor 3 (CXCR3) triggering microglial activation and proliferation. In the 
same manner, CX3C chemokine ligand 1 (CX3CL1) is released and is recognized by CX3C chemokine receptor 1 
(CX3CR1) inducing a neuroprotective response. CD200, a member of the immunoglobulin superfamily, is consti-
tutively expressed at the neuronal membrane surface, and its receptor CD200R is primarily present on microglia 
interaction. Milk fat globule factor 8 (MFG-E8) can be released by microglia and recognize externalized phospha-
tidylserine at the surface of apoptotic neurons. Autotaxin converts lysophosphatidylcholine (LPC) to lysophospha-
tidic acid (LPA), which can be perceived by microglia. 
3.3. The relevance of microglia in ALS progression 
As previously stated, microglia plays a key role in ALS progression. This importance was estab-
lished by studies such as those by Boillee and colleagues in mice showing that diminished levels of 
mSOD1 specifically in microglia greatly decrease disease progression (Boillee et al., 2006b). It was 
also proposed that this slowed disease progression is a consequence of the increased neurotoxicity of 
mSOD1G93A microglia when compared to WT microglia in microglia/MN co-cultures (Xiao et al., 
2007), where higher expression of NO and superoxide levels were found, together with a decreased 
expression of IGF-1. 
To further assess the effects of mSOD1 microglia in ALS pathoprogression, Beers et al. (2006) de-
veloped a knockout mouse model unable to produce myeloid cells, which was transplanted WT micro-
glia and found that this mice did not develop MN injury nor an ALS-like disease (Beers et al., 2006). 
Interestingly, replacement of microglia cells using clodronate liposomes, which specifically target 
monocyte/macrophage system (such as microglia cells), significantly slowed disease progression and 
prolonged survival of the transgenic ALS mice after bone marrow transplantation (BMT) (Lee et al., 
2012a). Nevertheless, influences of BMT may not be efficient enough since microglia are replaced by 
tissue-resident microglia rather than bone marrow cells (BMCs) (Ohnishi et al., 2009). Altogether, 
these studies indicate a pivotal role for microglia during the progression of the disease, as well as a 
putative beneficial role of healthy microglia in rescuing MN degeneration in ALS in vitro and in vivo 
animal models.  
4. Therapeutic approaches – recent findings 
ALS is a devastating MN disease characterized by progressive wasting and weakness leading to 
respiratory failure and death. Despite the advances in the comprehension of the mechanisms that trig-
ger neurodegeneration in ALS, there is not an effective treatment for this disease. Currently, the strat-
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egies that are being developed use pharmacotherapy, physical therapy, gene therapy, stem-cell ther-
apy, RNA therapy and immunotherapy areas. 
The only available drug approved by the American Food and Drug Administration (FDA) is the 2-
amino-6-trifluoromethoxy-benzothiazole (Riluzole) which has been shown to prolong survival of ALS 
patients only by a few months. Riluzole aims to perverse neuronal motor function by exerting its neu-
roprotective effects through blocking both voltage-gated sodium channels (Na+) and NMDA receptors, 
thereby preventing excessive calcium influx into neurons (Pratt et al., 2012; Venkova-Hristova et al., 
2012). Riluzole modulates GABAergic systems and acts as Ca2+, Na+ channel blocker with anti-
depressant and anti-convulsant properties (Pandya et al., 2012). The drug was tolerated well, but sur-
vival was extended by only 2-3 months compared with placebo. Other medications targeting glutamate 
pathways in neurons – talampanel, memantine, topiramate, pamotrigine, gabapentin and ONO2506 – 
have been studied, but all trials have been negative (Zinman and Cudkowicz, 2011). Inactivation of 
synaptic glutamate is a key function of the EAAT2 glutamate transporter on astrocytes in the protec-
tion of MNs from toxic effects. Cetftriaxone, a beta-lactam antibiotic, increased astrocyte-mediated 
glutamate transport by stimulating expression of EAAT2 in an in vitro blind screening study of 1040 
medications approved by the US FDA. In an animal model of ALS, use of this compound was associ-
ated with prolonged survival and upregulated transcription of mRNA for EAAT2 (Zinman and 
Cudkowicz, 2011). 
Stem cells have the potential to develop into many different cell types in the body during early life 
and growth. There are two kinds of stem cells in animals and humans: embryonic stem cells (ESC) 
and somatic or adult stem cells. The potential of stem cell therapies in neuronal replacement and re-
generation, as well of other neural tissues, has become a source of great hope and expectation for 
ALS patients. Stem cell therapy in ALS comprises two approaches: cell replacement and neural pro-
tection (Meamar et al., 2013). Cell replacement involves the substitution of dead neurons of the spinal 
cord with stem cell-derived spinal MN precursors, while neural protection aims to supply trophic fac-
tors to support and preserve endogenous cells (Mazzini et al., 2003; Mitchell and Borasio, 2007). 
Studies in mSOD1 rats show a delay in disease onset and prolonged survival by providing genetically 
non-compromised supporting cells (Xu et al., 2009). It has been reported that transplantation of autol-
ogous mesenchymal stem cells into the SC of ALS patients is safe and well tolerated (Mazzini et al., 
2003). More recently, the use of induced pluripotent stem cells has generated a great deal of attention 
due to their ability to differentiate into MNs. However, stem-cell treatment requires much work to be 
done before this treatments can be regarded as an experimental therapeutic for ALS. The potential of 
induced pluripotent stem cells (iPSCs) has attracted a great deal of attention due to its potential. 
Namely, Nizzardo et al. (2014) have observed beneficial effects of injecting iPSC-derived NSCs in 
ALS mice (Nizzardo et al., 2014). 
Among other mechanisms, loss of neurotrophic support to MNs has been implicated in the patho-
genesis of ALS (Pandya et al., 2012). A deficiency of growth factor support could provoke MN death in 
patients in ALS (Zinman and Cudkowicz, 2011). Various growth factors including GDNF, brain-derived 
neurotrophic factor (BDNF), VEGF, and IGF-1 are expressed differently in ALS, and all have enor-
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mous neuroprotective influence and promote proliferation among MNs in ALS (Federici and Boulis, 
2012). Viral delivery of IGF-1, glial-cell-derived neurotrophic factor (GDNF) and VEGF to MNs in the 
SOD1G93A mouse models prolongs their survival (Turner and Talbot, 2008; Vincent et al., 2008).  
Gene therapy involves the usage of a vector, most commonly viral, to deliver the therapeutic gene 
of interest to the affected region or tissue. Vaccines targeting SOD1G93A have been developed and 
shown to be effective in mouse models of ALS (Takeuchi et al., 2010). Also, SOD1 gene-silencing ap-
proach may be useful to delay disease onset or progression. Intraventricular infusion of antisense 
DNA oligonucleotides is one such approach. It reduces SOD1 protein and mRNA in the brain and spi-
nal cord (Smith et al., 2006). 
RNA interference (RNAi) is a mechanism of gene silencing in which siRNAs target cellular mRNAs 
for degradation. Therapies using small interfering RNA (siRNA) have shown down-regulation in human 
mutant SOD1G93A gene in lumbar SC of ALS mice (Rizvanov et al., 2009). miR-206 is a skeletal 
muscle–specific micro RNA that is a key regulator of signaling between neurons and skeletal muscle 
fibers at neuromuscular synapses. Mice that are genetically deficient in miR-206 have accelerated 
ALS progression. Because miR-206 mediates its action partially through histone deacetylase-4 and 
fibroblast growth factor signaling pathways, it delays ALS progression and promotes regeneration of 
neuromuscular synapses in mice. miR-206 also leads to regeneration of neuromuscular synapses 
(Williams et al., 2009). 
Animal models of ALS provide unique opportunities to study this lethal human disease both clinical-
ly and pathologically. ALS animal models have allowed controlled testing of various pathogenic mech-
anisms and arise as a medium clinical research and development. 
5. SOD1G93A mouse model for studying degeneration in ALS 
The development of experimental of both in vitro and in vivo models is essential for the study of 
cellular and molecular pathophysiological mechanisms of neurodegenerative diseases. As previously 
mentioned, mutations in SOD1 are one of the most frequent in fALS, together with the characteristic 
inclusions of mSOD1 being also present in sALS conceives the establishment mSOD1 models as one 
of the most widely studied models. Such models include mice, rats, zebrafish, Drosophila melano-
gaster and Caenorhabditis elegans (Joyce et al., 2011). Although none of these models are capable to 
fully mimicking the pathological and behavioral features of ALS, they still provide a valuable platform 
for the testing of pathogenic hypotheses. 
Approaches for the study of cellular and molecular pathophysiological mechanisms of ALS includes 
in vitro models. There is a wide array of these models, namely primary spinal cord cultures, NSC-35 
cell lines expressing mSOD1 as well as organotypic cultures (Tovar et al., 2009). For instance, prima-
ry spinal cord cultures allowed for the identification of MN vulnerability to glutamate excitotoxicity 
through overstimulation of AMPA receptors (Carriedo et al., 1996), while using the NSC-34 cell line 
Golgi apparatus fragmentation and mitochondrial dysregulation were described (Gomes et al., 2008; 
Raimondi et al., 2006) and finally resorting to organotypic cultures there was identification of neu-
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rotrophic factors acting to protect MNs from excitotoxicity (Tolosa et al., 2008). The knowledge ob-
tained using in vitro models can present itself as clues for further studies in vivo models as the latter 
doesn’t present the same limitations and better presents correlations between cellular alterations as 
well as motor behavior which can only be obtained in the whole animal. 
The first animal model was developed by Gurney and collaborators (1994) where they created a Tg 
mouse that expressed the human SOD1 gene with a substitution of a glycine for an alanine at position 
93 (G93A) (Gurney et al., 1994). The construct generally comprises 12-15 kb human genomic frag-
ments encoding SOD1 driven by the endogenous promoter and regulatory sequences (Turner and 
Talbot, 2008). Currently, there are 177 different SOD1 human ALS mutations expressed in the mouse 
as well as artificially induced SOD1 mutant transgenes that either prevent copper binding (Turner and 
Talbot, 2008). Most mutations are missense, however there are C-terminally truncated variants. Dif-
ferent SOD1 mutants reveal a degree of variation of transgene copy number, transcript and protein 
levels, enzymatic activity and neuropathology, however, a common feature is the induction of fatal 
symptoms (Julien and Kriz, 2006). These mSOD1 mouse models include G37R, G85R, D90A and 
G86R that show a similar phenotype as the SOD1G93A model (Van Den Bosch, 2011).  
The disease in SOD1G93A mice begins with hind limb tremor, impaired leg extension and reduced 
stride length around three months. These symptoms develop to hyperreflexia and complete paralysis 
of the limbs culminating in premature death at around 4 months of age (Dal Canto and Gurney, 1994; 
Durand et al., 2006; Turner and Talbot, 2008). Neuromuscular junctions degenerate around 47 days, 
which appears selective for fast-fatigable axons (Fischer et al., 2004), although a report by Gould et al. 
(2006) places peripheral denervation earlier at 25 days (Gould et al., 2006). Proximal axonal loss is 
prominent at 80 days and is concomitant with motor impairment and a severe 50% drop-out of lower 
MNs is evident at 100 days (Fischer et al., 2004). These data support that ALS is a dying back axo-
nopathy (Ferraiuolo et al., 2011). However, there is controversy about where the disease begins with 
the dying forward hypothesis proposing that the MNs in the cortex are the main part of the disorder, 
connecting with anterior horn cells thus mediating anterograde degeneration of anterior horn cells via 
glutamate excitotoxicity (Kiernan et al., 2011). Pathologic features include mitochondrial vacuolization, 
Golgi apparatus fragmentation, neurofilament-positive inclusions and cytoplasmic immune-reactive 
mSOD1 aggregates (Dal Canto and Gurney, 1995; Tu et al., 1996). There is also suggested a marked 
astroglial and microglial activation around symptom onset (Turner and Talbot, 2008; Van Den Bosch, 
2011). Degeneration of cranial nuclei such as trigeminal, facial and hypoglossal nerves also occurs in 
mice (Angenstein et al., 2004; Zang et al., 2004). Phenotypically, the symptom age onset and its se-
verity is directly proportional to the amount of SOD1 expressed in the tissue, supporting the hypothe-
sis of gain of toxic function of mSOD1 (Tovar et al., 2009). Expression of different SOD1 gene muta-
tions leads to different biochemical properties in Tg mice, even in the presence of endogenous 
mSOD1 gene, triggering the development of a neurodegenerative disease similar to the human illness 
(Ripps et al., 1995). 
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Figure I.6. Schematic time progression of amyotrophic lateral sclerosis (ALS) in mSOD1 mice.  Phenotypic 
differences between control (WT) mice and high copy number transgenic SOD1G93A mice (mSOD1) show mus-
cle atrophy of mSOD1 mice. Clinically, mSOD1 mice exhibit hindlimb tremor, weakness and locomotor deficits at 
about 30 days old which then evolves into paresis and progressive paralysis culminating in premature death at 
around 120 days. On a cellular level, Motoneuron degeneration is preceded by distal synaptic and axonal degen-
eration. Progressive astrocytosis and microgliosis is observed at 90 days old. On a molecular approach, progres-
sive mSOD1 aggregation is observed resulting in insoluble protein complexes (IPC), inclusion bodies modified by 
the ubiquitin-proteasome system (UPS) resulting in increasing endoplasmic reticulum (ER) stress. Furthermore, 
increasing Golgi degeneration and mitochondria dysregulation trigger apoptosis. Adapted from Turner et al. 
(2008). 
Other mSOD1 models present similar phenotypes as the G93ASOD1 mouse line. For instance the 
D90ASOD1 mutation shows more stability, however it is not as neurotoxic as other SOD1 mutants 
(Jonsson et al., 2009; Jonsson et al., 2006). The G86R model also indicate a possible gain of toxic 
function by the mSOD1 protein as well symptoms onset around 3 months of age with of paralysis lead-
ing to premature death around 4 months (Ripps et al., 1995). Watanabe and colleagues (2005) devel-
oped a model with a 2-base pair deletion at codon 126 of the SOD1 gene, where the mice start with 
symptoms of hindlimb paraparesis around 14 months progressing to muscle atrophy and death within 
40 days (Watanabe et al., 2005). The homozygous strains, although phenotypically indistinguishable 
from their heterozygous counterparts, exhibit mean ages of onset of the disease and die earlier. 
Further developed models include TDP-43 and FUS mutations. Mouse models overexpressing 
TDP-43 show toxicity and suffer neuronal loss (D'Alton et al., 2014; Xu et al., 2011). Studies by Veer-
beeck and colleagues (2012) show accumulation of FUS in the cytoplasm comparatively to WT, with 
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the degree of this shift correlating to the severity if the FUS mutation as reflected by disease onset in 
humans (Verbeeck et al., 2012). 
Rodent models, such as mSOD1, have the advantage of a consistent motor phenotype; readily 
available, low maintenance; homologous basic neuromuscular structures to humans and a short life 
cycle (Mead et al., 2011). Presenting common pathological feature between different models is pro-
gressive accumulation of aggregates containing SOD1 protein and aberrant neurofilament accumula-
tions in degenerating MNs, mSOD1 is still the most used animal model for the study of ALS. 
6. Aims 
The aims of this thesis are to evaluate molecules involved in cellular dysfunction and reactivity in 
ALS pathogenesis and to identify motoneuron-glia signaling pathways that are altered along ALS pro-
gression. This will be achieved by using samples obtained from lumbar spinal cord of the transgenic 
mice carrying a human mutant SOD1G93A gene, B6SJL-TgN (SOD1-G93A) 1Gur/J (mSOD1), at two 
different stages of disease progression: presymptomatic (4-6 weeks) and symptomatic (14-16 weeks). 
Results will be compared to similar samples obtained from the control B6SJLF1/J (WT) mice.  
The specific aims are: 
1. To evaluate both mRNA and protein expression levels of specific glial makers involved in 
ALS onset and progression, namely GFAP and S100B for astrocytes and CD11b for mi-
croglia. 
2. To evaluate both mRNA and protein expression levels of gap junction components (Con-
nexin 43 and Pannexin 1) involved in cell-cell communication and proliferation and migra-
tion markers Ki-67 and Autotaxin. 
3. To evaluate both mRNA and protein expression levels of motoneuron-microglia dialogue 
pathways, namely CXCR3-CCL21, CX3CR1-CX3CL1 and MFG-E8. 
4. To evaluate both mRNA and protein expression levels of inflammation-related molecules, 
namely TLR2, HMGB1, IL-18 and NLRP3. 
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  II. MATERIALS AND METHODS 
1. Materials 
1.1. Animals 
Transgenic B6SJL-TgN (SOD1-G93A)1Gur/J males (Jackson Laboratory, No. 002726) overex-
pressing the human SOD1 gene carrying a glycine to alanine point mutation at residue 93 (G93A) 
(Gurney et al., 1994) and wild-type B6SJLF1/J females were purchased from The Jackson Laboratory 
(Bar Harbor, ME, USA) and were breed at Instituto de Medicina Molecular rodent facilities where a 
colony was established. Maintenance and handling was performed according to the European Com-
munity guidelines (Directives 86/609/EU and 2010/63/EU, Recommendation 2007/526/CE, European 
Convention for the Protection of Vertebrate Animals used for Experimental or Other Scientific Purpos-
es ETS 123/Appendix A) and Portuguese Laws on Animal Care (Decreto-Lei 129/92, Portaria 
1005/92, Portaria 466/95, Decreto-Lei 197/96, Portaria 1131/97). The protocols used in this study 
were approved by the Portuguese National Authority (General Direction of Veterinary) and by the Eth-
ics Committee of the Institute of Molecular Medicine. Every effort was made to minimize the number of 
animals used and their suffering. 
mSOD1 mice were used to study presymptomatic (4–6 weeks old) and symptomatic (12–14 weeks 
old) phases of the disease. 4–6 and 12–14 weeks old wild-type (WT) animals served as controls. Both 
male and female mice were used in a 1:1 proportion as no gender influences over the intrinsic fea-
tures of neuromuscular transmission have been detected in this model (Rocha et al., 2013). Mice were 
anesthetized with a lethal dose of Pentobarbital and intracardially perfused. For quantitative real time 
transcription polymerase chain reaction (qRT-PCR) or Western blot (WB), mice were perfused with 0.1 
M phosphate buffer at pH 7.4 and lumbar spinal cord dissected and rapidly frozen at -80ºC.  
1.2. Chemicals 
Bovine serum albumin (BSA) and β-mercaptoethanol were purchased from Sigma-Aldrich (St. Lou-
is, MO, USA). Nitrocellulose membrane was obtained from Amersham Biosciences (Piscataway, NJ, 
USA); sodium dodecyl sulfate (SDS) was acquired from Prolabo (Poole, UK); LumiGLO® was from 
Cell Signalling (Beverly, MA, USA); acrylamide, bis-acrylamide, Tween 20, glycerol, sodium chloride 
(NaCl) were obtained from Merck (Darmstadt, Germany); Bio-Rad’s Protein Assay Reagent was ob-
tained from BioRad Laboratories (Hercules, CA, USA); Complete, EDTA-free Protease inhibitor cock-
tail tables (Roche). All the other common chemicals were of analytical grade and were purchased ei-
ther from Sigma-Aldrich or Merck. 
1.3 Primers and Antibodies 
Primary antibodies: mouse polyclonal anti-CXCR3, rabbit polyclonal anti-MFG-E8, rabbit polyclonal 
anti-SOD1 were purchased from Santa Cruz Biotechnology® (Santa Cruz, CA, USA). Mouse monoclo-
nal anti-HMGB1 was acquired from BioLegend® (San Diego, CA, USA). Mouse anti-β-actin, rabbit pol-
yclonal anti-GFAP were obtained from Sigma-Aldrich (St. Louis, MO, USA).  
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Secondary antibodies: Horseradish peroxidase-labelled goat anti-rabbit IgG, horseradish peroxi-
dase-labelled goat anti-mouse IgG and horseradish peroxidase-labelled rabbit anti-goat IgG were pur-
chased from Santa Cruz Biotechnology® (Santa Cruz, CA, USA). 
Table II.1. Primer sequences for genes evaluated 
Gene Primer sequence 
ATX 
Fwd 5’- GAC CCT AAA GCC ATT ATT GCT AA -3’ 
Rev 5’- GGG AGG TGC TGT TTC ATG T -3’ 
CCL21 
Fwd 5’- CAG GAC TGC TGC CTT AAG TA -3’ 
Rev 5’- GCA CAT AGC TCA GGC TTA GA -3’ 
CD11b 
Fwd 5’- CAG ATC AAC AAT GTG ACC GTA TGG G -3’ 
Rev 5’- CAT CAT GTC CTT GTA CTG CCG CTT G -3’ 
CX43 
Fwd 5’- ACA GCG GTT GAG TCA GCT TG -3’ 
Rev 5’- GAG AGA TGG GGA AGG ACT TGT -3’ 
CX3CL1 
Fwd 5’-CTC ACG AAT CCC AGT GGC TT-3’ 
Rev 5’-TTT CTC CTT CGG GTC AGC AC-3’ 
CX3CR1 
Fwd 5’-TCG TCT TCA CGT TCG GTC TG-3’ 
Rev 5’-CTC AAG GCC AGG TTC AGG AG-3’ 
GFAP 
Fwd 5’- CCA AAC TGG CTG ATG TCT ACC -3’ 
Rev 5’- GCT TCA TCT GCC TCC TGT CTA -3’ 
HMGB1 
Fwd 5’- CTC AGA GAG GTG GAA GAC CAT GT-3’ 
Rev 5’-GGG ATG TAG GTT TTC ATT TCT CTT TC-3’ 
IL-18 
Fwd 5’-TGG TTC CAT GCT TTC TGG ACT CCT-3’ 
Rev 5’-TTC CTG GGC CAA GAG GAA GTG-3’ 
Ki-67 
Fwd 5’- CAG TAC TCG GAA TGC AGC AA -3’ 
Rev 5’- CAG TCT TCA GGG GCT CTG TC -3’ 
MFG-E8 
Fwd 5’- TGA CTT TGG ACA CAC AGC GT -3’ 
Rev 5’- GTG TAG AAC AAC GGG AGG CT -3’ 
NLRP3 
Fwd 5’-TGC TCT TCA CTG CTA TCA AGC CCT-3’ 
Rev 5’-ACA AGC CTT TGC TCC AGA CCC TAT-3’ 
PAN1 
Fwd 5’- TGT GGC TGC ACA AGT TCT TC -3’ 
Rev 5’- ACA GAC TCT TGC CCC ACA TTC -3’ 
S100B 
Fwd 5’- GAG AGA GGG TGA CAA GCA CAA -3’ 
Rev5’- GGC CAT AAA CTC CTG GAA GTC -3’ 
TLR2 
Fwd 5’- TGC TTT CCT GCT GAA GATT T -3’ 
Rev 5’- TGT ACC GCA ACA GCT TCA GG -3’ 
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Table II.2. Primary antibodies used and respective information 
Primary antibody Clonality Host Brand Dilution 
β-actin Monoclonal Mouse Sigma-Aldrich 1:5000 
CXCR3 Polyclonal Mouse Santa Cruz Biotechnology® 1:300 
GFAP Polyclonal Rabbit Sigma-Aldrich 1:750 
HMGB1 Monoclonal Mouse Biolegend® 1:200 
MFG-E8 Polyclonal Rabbit Santa Cruz Biotechnology® 1:125 
SOD1 Polyclonal Rabbit Santa Cruz Biotechnology® 1:500 
 
1.4. Equipment 
Mini-PROTEAN Tetra cell system used for Western Blot from Bio-Rad (Hercules, CA, USA). Micro-
plate reader (PR 2100) was also from Bio-Rad and it was used for spectrophotometric measurement 
of protein. For immunodetection in nitrocellulose membranes was used ChemiDocTM equipment from 
Bio-Rad Laboratories. Sonication of samples was performed in the Ultrasonic Processor UP100H 
(Hielscher-Ultrasound Technology, Teltow, Germany). For RNA quantification Nanodrop ND-100 
Spectrophotometer (NanoDrop Technologies) was used. qRT-PCR was performed on a 7300 Real-
Time PCR System (Applied Biosystems) using Luminaris Color HiGreen High ROX qPCR Master Mix 
(Thermo Scientific). 
2. Methods 
2.1. Quantitative Real-Time PCR assay 
Total RNA was extracted from spinal cord by using Trizol Reagent (Invitrogen). Briefly, sample tis-
sue was lysated by adding TRIzol reagent, homogenated and then freezed. Chlorophorm was added 
in 0.2 per ml then incubated for 2-3 minutes at room temperature. Then samples were centrifuged at 
12000 for 15 minutes and aqueous phase was recovered and precipitated with 0.5 ml of isopropyl per 
ml of TRIzol and incubated for another 10 minutes at room temperature. Samples were centrifuged at 
12000g for 10 minutes. Supernatant was removed and RNA pellet was washed with 75% ethanol. 
RNA sample was further centrifuged at 12000g for 5 minutes and 30 μl of DEPC water was and collect 
to a sterile tube.  
Total RNA was then quantified by using Nanodrop ND-100 Spectrophotometer (NanoDrop Tech-
nologies) and equal amounts of RNA were tested for qRT-PCR as usual in our lab (Mariano et al., 
2013). Results were normalized to β-actin and quantified using the mathematical model developed by 
Pfaffl (Pfaffl, 2001). 
Primer sequences used are listed in Table II.1. 
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2.2. Western Blot assay 
Homogenates from SC were obtained by adding ice radio-immunoprecipitation assay, a lysis buffer 
composed of 5% of Tris(hydroxymethyl)aminomethane (Tris) 1M pH=8, 1% of Ethylenediamine 
Tetraacidic acid (EDTA) 0,5M pH=8, 3% of NaCl 5M, 10% of NP-40, 50% glycerol, 0,1% SDS and pro-
tease inhibitor, and homogenized using Pellet pestles (Sigma). Then samples were sonicated during 
20 seconds and centrifuged at 14000 g for 10 min, at 4ºC, and the supernatants were collected and 
stored at -80ºC. Protein concentration was determined using the Bradford method (Bradford, 1976) 
using Bio-Rad’s Protein Assay Reagent. Equal amounts of protein were separated on a 10% or on a 
12% sodium dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE) and then transferred to a 
nitrocellulose membrane. After transfer, blotted membranes were incubated in blocking buffer [Tween 
20-Tris buffered saline (T-TBS) plus 5% (w/v) non-fat dried milk] at room temperature during 1 h. After 
that, membranes were incubated overnight at 4ºC with the primary antibodies specified in Table II.2., 
diluted in T-TBS with 5% BSA: After washing with T-TBS, the membranes were incubated at room 
temperature (RT) during 1 h with the respective secondary antibodies: goat anti-rabbit HRP-linked or 
goat anti-mouse HRP-linked (for each one 1:5000, Santa Cruz Biotechnology®), diluted in blocking 
solution. After washing membranes with T-TBS, chemiluminescent detection was performed using 
LumiGLO® reagent, bands were visualized in Chemidoc equipment and relative intensities of protein 
bands were analyzed using the Image LabTM analysis software, both from Bio-Rad Laboratories (Her-
cules, CA, USA). All the results were normalized to β-actin. 
2.3. Statistical analysis 
Results of at least four different experiments were expressed as mean ± SEM. Comparisons be-
tween the different parameters evaluated in WT and mSOD1 mice were made using two-tailed Stu-
dent’s t-test for equal or unequal variance, as appropriate. Comparison of more than two groups (con-
sidering analysis between WT and mSOD1 either in presymptomatic and in symptomatic stages) was 
done by one-way Analysis of Variance (ANOVA) using GraphPad Prism 5 (GraphPad Software, San 
Diego, CA, USA) followed by multiple comparisons Bonferroni post-hoc correction. p<0.05 was con-
sidered statistically significant and p<0.01 very significant. 
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III. RESULTS 
ALS has been characterized as non-cell autonomous disease where glial cells play a pivotal role 
for its onset and progression, where neuroinflammation is an important hallmark of the disease, where 
microglia can acquire neurotoxic or neuroprotective properties (Evans et al., 2013). Astrocytes may 
also have an important roles related with excitotoxicity observed in ALS as well as inflammation, to-
gether with alterations in astrocytic phenotypes and function in SOD1 mouse models (Diaz-Amarilla et 
al., 2011; Philips and Robberecht, 2011). Therefore, a better understanding of MN-microglia dialogue 
during ALS onset and progression becomes necessary for discerning its pathoprogression.  
The mSOD1 mouse model used in the present work was first developed by Gurney and colleagues 
(1994). These mice overexpress human SOD1 inducing fatal symptoms strongly indicative of ALS and 
currently serve as one of the most used models for the study of the disease. 
Here, we evaluated either mRNA and/or protein expression levels of markers that could indicate 
astroglial or microglial reactivity and degeneration, as well as molecules involved in MN-glia signaling 
pathways in the spinal cord of mSOD1 mice at different stages of disease progression, namely at pre-
symptomatic (4-5 weeks) and at symptomatic (14-15 weeks) stages.  
1. Glial cell response and cellular communication are damaged in spinal cord of mSOD1 mice 
at presymptomatic stage 
1.1. SOD1 expression is increased in SC of mSOD1 mice 
We first evaluated the expression of SOD1. As shown in Figure III.1 our data reveal the presence 
of a band with molecular weight around 21 kDa, correspondent to human SOD1 (Kikuchi et al., 2006) 
only in mSOD1 mice. In addition, when normalized to the amount of mouse SOD1, we observed sig-
nificantly higher SOD1 expression in mSOD1 mice in comparison to WT (p<0.05), confirming that 
SOD1 accumulation occurs in our experimental model. 
 
Figure III.1. SOD1 expression is increased in the spinal cord 
(SC) from presymptomatic mSOD1 mice when compared to 
aged-matched control (WT). Samples were obtained as indi-
cated in Methods. Results are expressed as mean (± SEM) from 
six independent experiments *p<0.05 vs. matched WT mice us-
ing two-tailed unpaired Student´s t-test. 
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1.2. Glial cellular markers, hemichannels and proliferation indicators are diminished in SC from 
mSOD1 at PS phase  
Since ALS pathology is not exclusively a MN-disease, we then studied markers associated with 
proliferation and reactivity of glial cells associated to disease progression, namely astrocytes and mi-
croglia. First, we observed that astrocytic markers are diminished in the presymptomatic stage at the 
level of both mRNA (p<0.05) and protein (p<0.05) (Figure III.2 A and B). Also, expression of mRNA 
S100B, which is a member of a multigenic family of Ca2+ binding protein mainly expressed by astro-
cytes is decreased (Figure III.2 C). The reduction of both cellular markers may indicate an impaired 
astroglial activation during the presymptomatic stage of the disease. We also evaluated the state of 
microglial activation through the evaluation of mRNA levels of CD11b, a known indicator of microglia 
activation (Saijo and Glass, 2011). As shown in Figure III.2 D, we also determined diminished levels of 
CD11b in mSOD1 mice when compared to control (p<0.05), suggesting lack of microglial activation as 
well at this phase. 
 
Figure III.2. Expression of markers for glial activation are decreased in the spinal cord (SC) from presymp-
tomatic mSOD1 mice when compared to aged-matched controls (WT). Samples were obtained as indicated 
in Methods. Results of mRNA GFAP (A), GFAP (B), mRNA S100B (C) and mRNA CD11b (D) are expressed as 
mean (± SEM) from four (mRNA GFAP), three (GFAP and S100B) and six (CD11b) independent experiments 
*p<0.05; **p<0.005 vs. matched WT mice using two-tailed unpaired Student´s t-test. 
 
Next, we focused our study on the evaluation of hemichannels activity. Connexins form gap junc-
tions that appose two cells and form channels for direct intercellular communication, through which 
intercellular second messengers, such as Ca2+ ions and small molecules, are exchanged (Barbe et al., 
2006). Astrocytes constitutes the cells that mainly express Cx43 (Orellana et al., 2009). At the mSOD1 
presymptomatic stage of ALS progression, mRNA expression of either Cx43 is markedly decreased 
(p<0.05) (Figure III.3 A), suggesting a decrease in hemichannel activity due to an impairment in as-
troglial communication capacity. PAN1 is expressed by neurons and glia (Penuela et al., 2013) allow-
ing cell-cell communication through channels permeable to ATP and also the propagation of Ca2+ 
waves. In addition, they play a role in the release of “find-me” signals of apoptotic cell clearance 
(Chekeni et al., 2010). In Figure III.3. we observed that PAN1 mRNA levels are significantly dimin-
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ished (p<0.05)  suggesting a deregulation in cellular communication and apoptotic pathways. Ki-67 
has a role in proliferation (Kreitz et al., 2000). As such, mRNA expression of Ki-67 was visibly de-
creased (p<0.05) when compared to control at presymptomatic stages, as portrayed in Figure III.3 C, 
thus proposing lessened cellular capacity for migration. 
 
Figure III.3. Hemichannel proteins Cx43 and PAN1 and proliferation marker Ki-67 are decreased in the 
spinal cord (SC) from presymptomatic mSOD1 mice when compared to aged-matched control (WT). Sam-
ples were obtained as indicated in Methods. Results of mRNA Cx43 (A), mRNA PAN1 (B) and mRNA Ki-67 (C) 
are expressed as mean (± SEM) from five (Cx43), four (PAN1) and three (Ki-67) independent experiments 
*p<0.05 vs. matched WT mice using two-tailed unpaired Student´s t-test. 
1.3. MN-microglia dialogue is impaired in SC from mSOD1 mice at presymptomatic stage 
Having observed such alterations at the level of glial function, we further explored MN-microglia 
communication. We focused on the following axis: CXCR3-CCL21, CX3CR1-CX3CL1 and phagocyto-
sis mediated through MFG-E8.  
CXCR3-CCL21 signaling has not been studied in ALS context. CXCR3 is a receptor present in mi-
croglia which recognizes CCL21, a chemokine released by neurons that acts a chemokine that acts to 
drive microglia to the site of lesion and potentiate inflammation in conditions of spinal cord injury, when 
it’s expressed by apoptotic neurons (Biber et al., 2008). Although astrocytes also have CXCR3, they 
do not respond in terms of proliferation unless high levels of CCL21 occur (van Weering et al., 2010). 
CXCR3 protein expression is unaffected in mSOD1 when compared to control levels (Figure III.4.A). 
However, CCL21 mRNA levels are significantly decreased (p<0.05) during the presymptomatic stage 
(Figure III.4.B). CCL21 decrease suggests decreased microglial mobility and lack of astrocytitc. 
On the other hand, CX3CR1-CX3CL1 communication may have a role in enhancing neuroprotec-
tion, through the modulation of microglial proliferation (Appel et al., 2011). As demonstrated in Figure 
III.4 C and D, we observed a marked decrease (p<0.05) in mRNA expression of both these molecules, 
suggesting decreased neuroprotection capacity, due to its role in microglial proliferation and phagocyt-
ic properties and reducing neuronal apoptosis (Deiva et al., 2004). 
Interestingly, MFG-E8 MRNA and protein levels were also decreased (p<0.05) in mSOD1 pre-
symptomatic mice (Figure III.4 E and F), suggesting compromised phagocytic capacity at this ALS 
stage. Since MFG-E8 expression is directly implicated by CX3CL1 expression (Leonardi-Essmann et 
al., 2005), these results may indicate possible weakening in phagocytic capacity. Indeed, MFG-E8 
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seems to be essential for microglia engulfment and removal of dying neurons therefore acting as a 
phagocytic ability marker (Fuller and Van Eldik, 2008). This may however, be lost if the cell is continu-
ously stressed by a neurotoxic stimulus.  
 
Figure III.4. MN-microglia communication is impaired in the spinal cord (SC) from presymptomatic 
mSOD1 mice when compared to age-matched control (WT). Samples were obtained as indicated in Methods. 
Results from CXCR3 (A), mRNA CCL21 (B), mRNA CX3CR1 (C), mRNA CX3CL1 (D), mRNA MFG-E8 (E) and 
MFG-E8 (F) are expressed as mean (± SEM) from four (CXCR3, CX3CR1 and MFG-E8) and five (CCL21, 
CX3CL1 and mRNA MFG-E8) independent experiments *p<0.05 vs. matched WT mice using two-tailed unpaired 
Student´s t-test. 
ATX is also involved in microglial migration, alongside proliferation (Perrakis and Moolenaar, 2014). 
Thus, ATX expression was evaluated. In SC from mSOD1 mice, Figure III.5 shows that ATX levels are 
decreased compared to control samples. This seems to indicate an impairment in cellular migration 
and also could provide a potentiation in neuroinflammation as overexpression of ATX inhibits microgli-
al activation and migration (Awada et al., 2012). 
 
Figure III.5. Autotaxin (ATX) expression showed to be slightly 
decreased in the spinal cord (SC) from presymptomatic mSOD1 
mice when compared to age-matched control (WT). Samples 
were obtained as indicated in Methods. Results are expressed as 
mean (± SEM) from at least four independent experiments *p<0.05 
vs. matched WT mice using two-tailed unpaired Student´s t-test. 
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1.4. Inflammation-related markers are altered in SC of mSOD1 mice 
Since progressive neuroinflammation is a hallmark of ALS, the study of inflammation-related mole-
cules is imperative. Additionally, our previous results show a lack of neuroprotective capacity which 
may be related to progressive neuroinflammation. Accordingly, TLR2 a pattern recognition receptor, 
which can recognize mSOD1 (Zhao et al., 2010), is increased at the presymptomatic stage (Figure 
III.5.A) possibly indicating an attempt of immune cells, such as microglia, to produce an inflammatory 
response. Regarding HMGB1, an alarmin that can be released by astrocytes, microglia and neurons 
(mainly when cells are dying) (Gao et al., 2011; Lo Coco et al., 2007), we found that this alarmin is 
significantly decreased (p<0.05) in the SC of presymptomatic stages as illustrated by Figure III.6. Pro-
tein expression was also evaluated but revealed apparent unaltered levels (0.92 fold, see Annex 1.1). 
Since HMGB1 can interact with TLR2 due to the decrease of HMGB1, TLR2 could be overcompensat-
ing its lack thereof (Casula et al., 2011). Another inflammatory indicator that we have measured is IL-
18, which slightly increased at presymptomatic stage (Figure III.6.C).  In addition, the inflamasomme 
component NLRP3 showed a significant decrease (p<0.05) when compared to control values (Figure 
III.6.D), consequently indicating an impairment of the inflammatory response. 
 
Figure III.6. Inflammatory-related biomarkers are altered in the spinal cord (SC) from mSOD1 mice when 
compared to age-matched control (WT). Results from mRNA TLR2 (A), mRNA HMGB1 (B), mRNA IL-18 (C) 
and mRNA NLRP3 (D) are expressed as mean (± SEM) from four independent experiments *p<0.05 vs. matched 
WT mice using two-tailed unpaired Student´s t-test. 
Altogether these results indicate lack of glial cell activation and damaged cellular communication 
with an affected inflammatory response. 
2. Spinal cord from mSOD1 mice at symptomatic stage is characterized by an exacerbated in-
flammatory environment 
The transition from the presymptomatic phase to the symptomatic phase is accompanied by a 
number of alterations both at clinical and molecular levels (Turner and Talbot, 2008). Following the 
same rationale of the previous section, we investigated possible alterations in the same aspects of the 
symptomatic stage. 
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2.1. SOD1 expression is increased in SC of mSOD1 mice 
As illustrated in Figure III.7, we observed higher SOD1 protein levels in mSOD1 mice than in those 
from WT expression (p<0.05).   
 
 
Figure III.7. SOD1 expression is increased in the spinal cord (SC) 
from symptomatic mSOD1 mice when compared to aged-matched 
control (WT). Samples were obtained as indicated in Methods. Results 
are expressed as mean (± SEM) from six independent experiments 
*p<0.05 vs. matched WT mice using two-tailed unpaired Student´s t-
test. 
 
2.2. Glial cell activity, communication and proliferation capacities are increased in SC of 
mSOD1 mice at symptomatic stage 
Regarding cellular markers, namely astrocytic marker GFAP, we observed a significant increase in 
mRNA levels (Figure III.8.A, p<0.05 vs. WT), but a decrease was found for protein expression (Figure 
III.8.B, p<0.05 vs. WT). This lower protein content may possibly indicate the presence of an astrocyte 
population with an aberrant phenotype, as if has been suggested by some authors in mSOD1 rats 
(Diaz-Amarilla et al., 2011). Accordingly, mRNA levels of S100B were slightly increased as compared 
to control samples (Figure III.8.C). 
In addition, as illustrated in Figure III.8.D, mRNA expression of CD11b was also markedly in-
creased (p<0.01 vs. WT), suggesting that microglia is also activated during the symptomatic stage of 
the disease. 
 
Figure III.8. Expression of markers for glial activation are increased in symptomatic stage of mSOD1 mice 
when compared to aged-matched controls (WT). Samples were obtained as indicated in Methods. Results of 
mRNA GFAP (A), GFAP (B), mRNA S100B (C) and mRNA CD11b (D) are expressed as mean (± SEM) from four 
(GFAP and S100B) and six (CD11b) independent experiments *p<0.05 vs. matched WT mice using two-tailed 
unpaired Student´s t-test. 
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Furthermore, we found increased mRNA expression of both Cx43 and PAN1 of symptomatic 
mSOD1 mice (Figures III.9.A and B), suggesting larger communication between cells at this stage. 
Expression of mRNA Ki-67 was also elevated (Figure III.9.C), indicating an increase in cellular prolif-
eration. 
 
Figure III.9. Connexin 43 (Cx43) and proliferation marker Ki-67 are decreased in the spinal cord (SC) from 
symptomatic mSOD1 mice compared to control (WT), but no changes were noticed in Pannexin 1 (PAN1). 
Samples were obtained as indicated in Methods. Results of mRNA Cx43 (A), mRNA PAN1 (B) and mRNA Ki-67 
(C) are expressed as mean (± SEM) from five (Cx43), four (PAN1) and three (Ki-67) independent experiments 
*p<0.05 vs. matched WT mice using two-tailed unpaired Student´s t-test. 
In relation to MN-microglia dialogue, the CXCR3-CCL21 axis was positively affected revealing a 
slight enhancement of CXCR3 (Figure III.10.B) and mRNA CCL21 (p<005) (Figure III.10.B) expression 
levels. This increase suggests higher microglial mobility towards the site of lesion (Biber et al., 2007).  
Likewise, the CX3CR1-CX3CL1 axis was also significantly increased in mSOD1 vs. WT as depict-
ed in Figures III.10.C and D (p<0.05), respectively, suggesting an attempt to modulate the inflammato-
ry microglial response (Briones et al., 2014). Additionally, both mRNA and protein expression levels of 
MFG-E8 (Figures III.10.E and F, respectively) were also increased in mSOD1 mice, proposing higher 
microglial phagocytic capacity at symptomatic stage (Appel et al., 2011). 
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2.3. MN-microglia signaling is increased in SC of mSOD1 at S stage 
 
Figure III.10. MN-microglia communication is increased in the spinal cord (SC) from symptomatic mSOD1 
mice when compared to aged-matched controls (WT). Samples were obtained as indicated in Methods. Re-
sults from CXCR3 (A), mRNA CCL21 (B), mRNA CX3CR1 (C), mRNA CX3CL1 (D), mRNA MFG-E8 (E) and 
MFG-E8 (F) are expressed as mean (± SEM) from three (CXCR3 and MFG-E8), four (CX3CL1, CCL21 and 
mRNA MFG-E8) and five (CX3CR1) independent experiments *p<0.05 vs. matched WT mice using two-tailed 
unpaired Student´s t-test. 
Regarding the evaluation of cellular migration and proliferation, we observed in Figure III.10 that 
there was a rise in mRNA expression of ATX. This shift could be an attempt to promote inhibition of 
microglial activation, as well as to confer higher oxidative stress protection (Awada et al., 2012). 
 
Figure III.11. Autotaxin expression is increased in the spinal cord 
(SC) from symptomatic mSOD1 mice compared to aged-matched 
controls (WT). Samples were treated as indicated in Methods. Re-
sults are expressed as mean (± SEM) from four independent experi-
ments *p<0.05 vs. matched WT mice using two-tailed unpaired Stu-
dent´s t-test. 
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2.4. Inflammation-related markers are altered in SC of mSOD1 mice at symptomatic stage 
Finally, addressing neuroinflammation-related molecules we show in Figure III.12.A a slight de-
crease mRNA expression of TLR2 in symptomatic mSOD1, however other inflammatory markers were 
found be highly increased. Indeed, mRNA HMGB1 levels were significantly higher in symptomatic 
mSOD1 mice than in WT (p<0.01 vs. WT, Figure III.6.B), as well as HMGB1 protein expression (~1.35 
fold, see Annex 1.2). Analysis of IL-18 mRNA levels revealed a slight increase (Figure III.12.C), which 
was even higher for mRNA expression of NRLP3 (Figure III.12.D) suggesting the inflammasome acti-
vation at symptomatic phase of mSOD1 mice.  
 
 
Figure III.12. Inflammatory-related biomarkers are altered in the spinal cord (SC) from symptomatic 
mSOD1 mice compared to aged-matched controls (WT). Results from mRNA TLR2 (A), mRNA HMGB1 (B), 
mRNA IL-18 (C) and mRNA NLRP3 (D) are expressed as mean (± SEM) from four independent experiments 
*p<0.05 vs. matched WT mice using two-tailed unpaired Student´s t-test. 
Altogether, analysis of the SC from mSOD1 at symptomatic stage of ALS showed an increased cel-
lular activation and proliferation concomitant with elevated hemichannel activity, MN-microglia dia-
logue and inflammation-related molecules. These alterations seem to potentiate the pro-inflammatory 
state characteristic of the symptomatic phase of ALS. 
3. Evaluation of molecular markers variation along ALS pathoprogression 
After studying each individual phase, we performed an evaluation of the variation of each molecular 
marker along the progression of the disease. This analysis was accomplished by matching mSOD1 
from symptomatic stage against mSOD1 results from the pre-symptomatic stage and using one-way 
ANOVA followed by Bonferroni’s multiple comparison test. These results are summarized in Table 
III.1. 
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Table III.1. Variation of different markers between the presymptomatic and symptomatic stages of mSOD1 mice 
vs. aged-matched controls (WT). Results are expressed as mean (± SEM) from at least three independent exper-
iments *p<0.05, **p<0.005 and ***p<0.001 vs. matched mSOD1 mice using one-way ANOVA followed by Bonfer-
roni’s multiple comparison test. ↑, ↓ refer to an increase and decrease, respectively, of each molecule vs. respec-
tive control, with number of arrows referring to greater or lesser parameter variation. 
Molecule Presymptomatic Symptomatic 
Statistical variation be-
tween stages 
SOD1 (protein) ↑↑ ↑↑↑  
Cellular marker    
GFAP (mRNA/protein) ↓/↓ ↑↑/↓ ** 
S100B (mRNA) ↓ ↑  
CD11b (mRNA) ↓ ↑ *** 
Hemichannel activity    
CX43 (mRNA) ↓ ↑↑ *** 
PAN1 (mRNA) ↓ ↑ ** 
Ki-67 (mRNA) ↓ ↑↑ * 
MN-microglia dialogue    
CXCR3 (protein) ↑ ↑  
CCL21 (mRNA) ↓ ↑↑ ** 
CX3CR1 (mRNA) ↓ ↑↑ ** 
CX3CL1 (mRNA) ↓ ↑ *** 
MFG-E8 (mRNA/protein) ↓/↓ ↑/↑ * 
Proliferation and migration marker   
ATX (mRNA) ↓ ↑↑ ** 
Inflammatory-associated molecules   
TLR2 (mRNA) ↑↑ ↓  
HMGB1 (mRNA) ↓ ↑↑ *** 
IL-18 (mRNA) ↑ ↑  
NLRP3 (mRNA) ↓ ↑↑ *** 
 
These results show increasingly SOD1 accumulation in mSOD1 mice during disease progression. 
During the transition from a presymptomatic stage to the symptomatic stage there is a change in 
mRNA levels of both astrocytes (GFAP p<0.005) and microglia markers (CD11b p<0.001) indicating a 
shift from an inactivated stage during presymptomatic stage and activated during symptomatic phase. 
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In the same manner, hemichannels components (Cx43 p<0.001; PAN1 p<0.005) and proliferation 
marker Ki-67 (p<0.05) also present elevated expression when compared to control values at sympto-
matic stage. Accordingly, MN-microglia dialogue also present a turnover where communication is in-
creased at symptomatic stage. Specifically, CCL21 (p<0.005), CX3CR1-CX3CL1 (p<0.005 and 
p<0.001, respectively) and MFG-E8 (p<0.05) are significantly increased. Similarly, ATX changes from 
decreased levels at presymptomatic stage to an overexpression during the later stages of the disease 
(p<0.005). We also observed an increase of inflammatory factors namely HMGB1 (p<0.001) and 
NLRP3 (p<0.001) at symptomatic stage.  
Altogether these results distinguish two different roles for glial cells and inflammatory response be-
tween stages, with the presymptomatic stage presenting lack of glial cell activation and communica-
tion ability, impaired MN-microglia dialogue and inflammation incapacity. The symptomatic stage, 
however shows increased glial activation and communication together with high proliferation capacity, 
improved MN-microglia dialogue and strong inflammatory response.  
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IV. DISCUSSION 
Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by its progressive loss 
of MNs. Causes for ALS comprise both genetic and sporadic components and several studies have 
identified a role of glial cells for the pathoprogression of the disease, which makes ALS a very com-
plex and multifactorial disease. The study model of SOD1G93A (mSOD1) mice have provided great 
insights into the mechanisms of disease progression (Gurney et al., 1994; Turner and Talbot, 2008). 
As such, in the present work, we resorted to this mSOD1 model in order to evaluate mRNA and pro-
tein expression levels of several cellular markers with a main emphasis on glial function, as well as 
known MN-microglial communication pathways and molecular indicators inflammation. Our approach 
focused on the characterization of both presymptomatic and symptomatic disease stage in mSOD1 
mice, based on the study of each individual phase as well as on determination of the evolution of such 
biomarkers along disease progression. 
We first observed a significant increase of SOD1 protein expression in samples from the SC of 
mSOD1 mice at both phases of the disease, with a progressive accumulation of SOD1 levels with the 
course of the disease. Previous studies using SOD1G93A1 mice have also shown progressive accu-
mulation of human SOD1 in the spinal cord through Northern Blot and immunocytochemistry analysis 
(Cheroni et al., 2005). Abnormal protein folding and aggregation of SOD1, along with other proteins 
previously addressed in the Introduction section of this thesis, are a common pathological feature of 
ALS (Gurney et al., 1994; Vaz et al., 2014). These aggregates have been suggested as harmful 
through the sequestration of proteins required for normal MN function; reducing availability of chaper-
ones due to repeatedly misfolding; reducing proteasome activity and lead to inhibition of the function 
of specific organelles (e.g. mitochondria) by aggregation on or within these organelles (Shaw, 2005). 
As such, constant accumulation could aggravate these insults. Additionally, identification of extracellu-
lar mSOD1 inducing microglial-mediated MN injury through stimulation of TLR2/4 and CD14 triggering 
microgliosis and pro-inflammatory response in primary cultures of MNs and microglia (Zhao et al., 
2010) could be factors potentiating MN injury due to increasing mSOD1 accumulation. mSOD1 can be 
secreted through chromogranin mediation has also been linked to ALS (Urushitani et al., 2006). Fur-
ther studies should focus the state of aggregation of SOD1 in our model being a characteristic of ALS 
pathophysiology (Higgins et al., 2003). 
In order to evaluate glial cell response associated with SOD1 accumulation, we focused on cellular 
markers of astrocytes and microglia. Regarding astrocytes, our results show decreased mRNA and 
protein expression of the astrocytic marker GFAP, during presymptomatic stage of mSOD1 mice but 
increased levels of mRNA at symptomatic stage, suggesting that astrocytes are being differently mod-
ulated as disease progresses. In fact, astrocytes are known to release trophic factors to protect neu-
rons at the very beginning of insult (Gomez-Nicola et al., 2010) but they also may participate in the 
inflammatory response at later phases (Evans et al., 2013).  The diminished levels of GFAP, together 
with lessened S100B, a known marker of astroglial activation (Sofroniew and Vinters, 2010), found at 
presymptomatic stage probably indicate that at this time point, astrocytes lack of response capacity 
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from astrocytes. However, during the symptomatic phase, we found increased levels of S100B and 
GFAP mRNA expression, along with decreased protein expression of GFAP. Higher levels of S100B, 
together with Cx43 and PAN1 at this stage indicate astroglisosis. This phenotypic variation may be 
due to the previous results obtained by Diaz-Amarilla and colleagues (2011) (Diaz-Amarilla et al., 
2011) where they identified in primary SC cultures of symptomatic rats expressing SOD1G93A a phe-
notypically aberrant population of astrocytes in which they have increased S100B expression and 
Cx43 and decreased expression of GFAP, in which they lack expression of GLT-1. In addition, it is 
important to notice that at symptomatic stage, GFAP expression is only up-regulated in mSOD1 mice 
at the level of gene expression. The fact that it doesn’t translate into protein is probably a result of al-
tered mRNA processing, a proposed altered mechanism in ALS pathophysiology. (Ferraiuolo et al., 
2011). Another work observed a phenotypic transition of microglia into astrocyte-like cells associated 
with disease onset in a model of inherited ALS (SOD1G93A rats) (Trias et al., 2013), however it is 
hard to precisely pinpoint these alterations since we have no way to tell from which cells these GFAP 
alterations result. Another relevant study was done by Yoshii and collaborators (Yoshii et al., 2011) 
where they identified that the loss of GFAP marginally accelerates disease progression in SOD1H46R, 
as a consequence, the loss of GFAP we observed could also be contributing to disease progression, 
Regarding S100B expression, we found their levels diminished during presymptomatic stage of ALS 
suggesting lack of astrocytic proliferation at this stage (Brozzi et al., 2009). On the other hand, in-
creased S100B expression observed at symptomatic stage may result in higher astrocytic migration in 
mSOD1 mice. Also, as previously mentioned, phenotypically aberrant astrocytes overexpress S100B 
which could contribute to the increased levels we observed in our results, together with high Cx43 ex-
pression, and suggest the presence of an immature astrocytic phenotype at the symptomatic phase 
(Diaz-Amarilla et al., 2011).  
Regarding microglial activation, our results show down-regulation of mRNA expression of CD11b 
during the presymptomatic stage of ALS and a significant shift to higher levels of CD1b in mSOD1 
than control at the symptomatic phase. These results are in accordance with microglial activation and 
microgliosis characterized in ALS and the inflammatory state observed at the symptomatic phase 
(Liao et al., 2012). Altogether, these results indicate a prevalence of activated glial cells only at symp-
tomatic stage of ALS. 
In relation to connexins, our results show a significant decrease of mRNA expression levels of 
Cx43 during the presymptomatic stage of the disease. This supports the previous results of both 
GFAP and S100B results suggesting lack of astrocytic response during this phase of the disease. 
Some studies suggested that upregulation of Cx43 can be correlated with microglia activation (Kielian, 
2008), which  is also in accordance with our results showing lack of activation on both astrocytes and 
microglia in mSOD1 at presymptomatic stage. In addition, we were able to detect increased mRNA 
expression of Cx43 in mSOD1 at symptomatic stage, corroborating our assumption that at this time 
point there is an increase of glial activation. This is not without precedent since Cx43 is primarily ex-
pressed in astrocytes and its up-regulation leads to a reactive astroglisosis (Theodoric et al., 2012). 
Similarly, levels of PAN1, which  form hemichannel allowing for cell-cell communication and has a  
predominant neuronal origin (Barbe et al., 2006), were significantly decreased in presymptomatic 
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mSOD1, although slightly increased at symptomatic phase. Since these channels are permeable to 
ATP, allow for propagation of Ca2+ waves and play a role in the release of “find-me” signals of apoptot-
ic cell clearance (Chekeni et al., 2010), we may assume that there is a deregulation of cellular com-
munication that may also lead to diminished phagocytic abilities. In addition, we evaluated the mRNA 
expression of the proliferation marker, Ki-67 (Kreitz et al., 2000). Similarly to Cx43 and PAN1, Ki-67 
mRNA expression was decreased during the presymptomatic phase of ALS. Taken all these markers 
into account, our results infer lack of proliferating capacity during the earlier stages of the disease as 
well as lack of intercellular communication. At the symptomatic stage we identify a shift towards up-
regulation of mRNA expression compared to control values. This suggests a positive turnover be-
tween cell-cell communication from a down-regulation at the presymptomatic stage, to an increase at 
the symptomatic phase. Namely, higher PAN1 expression levels suggest that there might be an in-
crease of transmission of “find-me” signals for apoptotic clearance (Chekeni et al., 2010). Additionally, 
the overexpression of Ki-67 and Cx43 seem to have positive effects in microglial activation and prolif-
eration capacity (Homkajorn et al., 2010; Kreitz et al., 2000), hence contributing to a pro-inflammatory 
response at the symptomatic phase. 
Having identified a putative role for microglial activation in the pathophysiology of ALS, we explored 
known communication pathways between these cells and MNs. As such, we focused in the CXCR3-
CCL21 axis, which has never been studied in the context of ALS. We showed for the first time that at 
presymptomatic phase there is unaltered protein expression of CXCR3 and significant decrease in 
mRNA levels of CCL21, however at symptomatic stage we observed a huge increase in CCL21 in 
mSOD1 mice. CXCR3, a microglial receptor for CCL21 whose stimulation by CCL21 induces activa-
tion (van Weering et al., 2010) suggests that at the presymptomatic stage this axis of communication 
is impaired, therefore not producing a microglial response at this stage. Since neurons express CCL21 
in response to injury (Biber et al., 2001), these results suggest an alteration between the MN-microglia 
communication, where MNs are not able to release an injury response through chemokine CCL21. We 
can also extrapolate that there would be no astrocytic response due to low levels of CCL21 mRNA, 
since these cells are produce a response only when at higher CCL21 concentrations (van Weering et 
al., 2010).  Due to its chemotactic properties induced by the presence CCL21 (Biber et al., 2008), we 
can deduce that microglial mobility is compromised through this pathway during the presymptomatic 
phase of ALS. However, we found significantly increased levels of CCL21 in symptomatic phase, 
which, accordantly with the results obtained for Cx43, CD11b and Ki-67, indicate higher microglia pro-
liferation that may promote an inflammatory response to MN injury. Additionally, since CCL21 is able 
to interact with astrocytic receptor CCR7, which is found up-regulated after inflammatory injury induc-
ing astrocytic response (Gomez-Nicola et al., 2010), and associating this knowledge with observed 
astroglisosis in our studies, CCR7 may also be considered a good candidate to evaluate in order to 
assess whether CCL21 is affecting more microglial or astrocytic response at the symptomatic phase of 
ALS. 
Another described axis of communication between MNs and microglia is CX3CR1-CX3CL1. Our 
results show diminished mRNA expression of both CX3CL1 and its receptor during the presymptomat-
ic stage. This indicates that this axis might be severely compromised during this phase as not only 
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MNs have decreased capacity for releasing chemokines but as well as the capacity for microglia to 
recognize such signals and produce a neuroprotective response (Harrison et al., 1998). This impair-
ment is concomitant with our previously evaluated microglial response and proliferative factors at this 
stage. Nonetheless, during the symptomatic phase, we observed increased mRNA expression repre-
senting an increase in MN-microglial dialogue. Since higher levels of CX3CL1 could contribute to an 
increased inflammatory response due to its chemotactic ability and drawing activated microglia to-
wards the site of injury, our results identify microglial response at this stage as the probable cause to 
the inflammation also observed.  Furthermore, MN-microglia communication studies were focused on 
microglial release of MFG-E8, which recognizes phosphatidylserine as an “eat-me” signal expressed 
on the surface of apoptotic neurons (Fricker et al., 2012). Our results showed a significant decrease of 
both mRNA and protein expression of MFG-E8 during the presymptomatic phase of ALS, which may 
be related to lack of PAN1 hemichannels releasing “eat-me” signals, also required for phagocytosis 
(Chekeni et al., 2010). This result also proposes a damaged phagocytic response from microglia that 
will interfere with their communication with MNs and contribute to an overall diminished neuroprotec-
tive environment at the presymptomatic stage. However, MFG-E8 levels are increased at symptomatic 
stage, thus suggesting an increase in microglia phagocytic ability.  Also, studies show that CX3CL1 
up-regulates MFG-E8 expression (Leonardi-Essmann et al., 2005), which, together with higher levels 
of PAN1, our results show an increased phagocytic response, for which microglia activation and mi-
gration is required. Nevertheless, we may not conclude that the effect of a phagocytic microglia at 
symptomatic stage contributes to a neuroprotective effect, since microglia activation was also ob-
served at this time, as well as an inflammatory environment, as it will be further detailed in this chap-
ter.  
One of the possible intervenients that mediate this lack of microglial neuroprotection is autotaxin 
(ATX). ATX is involved in cellular processes like migration, proliferation and survival of various cells 
(Perrakis and Moolenaar, 2014). Since ATX promotes the conversion of LPC to LPA whose receptors 
are expressed by microglia, astrocytes and oligodendrocytes, this molecule has been pointed to play a 
key role in glial response to injury (Awada et al., 2012). Our results show decreased mRNA expres-
sion of ATX during the presymptomatic phase which suggests lack of cellular migration ability in 
agreement with our previously obtained results for this stage of ALS. ATX levels also indicate a shift 
between the presymptomatic and symptomatic phases, where we verify a significant increase in ATX 
mRNA expression after symptom onset which infer higher migration and proliferation capacity at this 
stage. These results support the alterations we identified for hemichannel components and MN-
microglia communication, where migration and proliferation markers are also up-regulated. Additional-
ly, studies have shown that secretion of ATX by microglial cells is stimulated by oxidative stress and 
that ATX overexpression reduces microglial ROS-mediated damage and microglial activation (Awada 
et al., 2012). As such, we might be observing an attempt to preserve microglial viability in detriment to 
an aggravation of inflammatory response also observed. 
Having identified a pattern of glial cell activation in our model, we further explored inflammation 
markers, since it may be considered a hallmark of ALS pathophysiology (Philips and Robberecht, 
2011). Our results show increased mRNA expression of TLR2 during the presymptomatic phase 
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which, combining with increased levels of SOD1 could be triggering an inflammatory response (Zhao 
et al., 2010).TLR2 is a pattern recognition receptor capable of recognizing mSOD1 aggregates as well 
as the alarmin HMGB1 and triggering an inflammatory cascade response. Studies using post-mortem 
human spinal cord cultures from ALS patients have shown increased TLR2, mainly in microglia line-
age, and HMGB1 mRNA expression levels at end stage of the disease (Casula et al., 2011). Liu et al. 
(2009) have shown that the expression of mSOD1 increases the neurotoxic potential of microglia via 
TLR2 (Liu et al., 2009).  However, at the symptomatic stage we observe a slight decrease in TLR2 
expression, which may indicate that the potentiation of the inflammatory response does occur through 
this pathway. 
Regarding HMGB1, we found decreased mRNA expression levels together with seemingly unal-
tered protein levels at presymptomatic stage. This molecule can act as a transcription factor for in-
flammatory response genes or be released to the extracellular medium and act upon TLR2/4 or RAGE 
receptors prompting an inflammatory response (Muller et al., 2004). As such, during the presympto-
matic phase this lack of mRNA HMGB1 may not translate in lack of activation of inflammation due to 
maintained levels of protein. On the other hand, during the symptomatic phase these expression lev-
els are increased which may potentiate the inflammatory response observed. Since TLR2 expression 
levels are decreased during this phase, it’s likely that HMGB1 is primarily acting on TLR4 and RAGE. 
Interestingly, according to Casula et. al (2011), TLR4 is primarily expressed in astrocytes (Casula et 
al., 2011), which suggest that in our model TLR4 is probably more activated than TLR2. Further stud-
ies taking into account both receptors will add our assumptions in order to better understand the mod-
ulation through HMGB1 in our model.  
Our results showed IL-18 mRNA levels to be slightly increased during the presymptomatic phase 
which could mean a slight attempt at an inflammatory response. IL-18 is an inflammatory cytokine that 
induces activation of Th1 cells and production of INF-γ. One of the inflammatory markers found in the 
CNS of ALS mice is active caspase-1, which is activated in response to danger signals by inflam-
masomes and proteolytically matures IL-1β and IL-18 (Meissner et al., 2010). After the transition to the 
symptomatic phase IL-18 expression levels only slightly increased, which suggest that the aggravation 
of the response may not be occurring through this pathway. 
Nevertheless, NLRP3 evaluation showed a significant decrease in mRNA expression in presymp-
tomatic mSOD1 mice. NLRP3 inflammasome can be induced by numerous stimuli, namely ROS. 
NLRP3 inflammasome can induce, through caspase-1, IL-18 and IL-1β maturation, the latter being a 
potent inflammatory factor (Heneka et al., 2013). Altogether, these results suggest a deficiency of in-
flammatory response during the presymptomatic stage. However, during the symptomatic stage we 
observed a significant increase in the expression levels of NLRP3 indicating marked pro-inflammatory 
response involving the formation of inflammasome components at this phase. Posterior measurement 
of IL-1β expression levels should be performed in order to better assess NLRP3 effects. Overall, these 
results suggest a pro-inflammatory environment in symptomatic mSOD1 mice, and that glia reactivity 
and MN-glial communication pathways may be aggravating this inflammatory response. 
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In conclusion and as schematically represented in Figure IV.1, our results show a distinct transition 
from a presymptomatic stage characterized by severe impairment of communication, glial and inflam-
matory responses to symptomatic phase where there is a pattern of glial activation with marked in-
crease of communication pathways and proliferation factors, together with striking intensification of 
neuroinflammatory response. Altogether, these results allow for a clear distinction between both stag-
es of the disease, which bring new insights to target specific molecules that lead to neurodegeneration 
in ALS. Interestingly, we hypothesize that by increasing autotaxin expression we may be able to delay 
ALS onset, before considering anti-inflammatory compounds to fight disease progression. 
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Figure IV.1. Schematic representation of the major findings of this Master Thesis. (A) Presymptomatic 
stage of amyotrophic lateral sclerosis (ALS) in mSOD1 mice evidence an increase in SOD1 accumulation. Glial 
cell markers show a decrease in astrocytic markers glial fibrillary protein (GFAP) and S100B and in microglial 
marker complement receptor CR3 (CD11b). Gap-junction components Connexin 43 (Cx43) and Pannexin 1 
(PAN1) are negatively affected. Motoneuron (MN)-microglia dialogue pathways, namely Chemokine (C-C motif) 
ligand 21 (CCL21) and chemokine (C-X-C motif) receptor 3 (CXCR3), CX3C chemokine receptor 1 (CX3CR1) 
Chemokine (C-X3-C motif) ligand 1 (CX3CL1) and milk fat globule factor-E8 (MFG-E8) is impaired. Proliferation 
marker Ki-67 and autotaxin levels are diminished. Inflammation-related molecules high mobility group box 1 
(HMGB1) and NOD-like receptor family, pyrin domain containing 3 (NLRP3) are negatively affected, while Toll-like 
receptor 2 (TLR2) and Interleukin 18 (IL-18) are increased.  (B) The symptomatic stage of ALS shows high accu-
mulation of SOD1. Astrocytic (GFAP and S100B) and microglial (CD11b) markers are increased. Gap-junction 
components Cx43 and PAN1 are elevated. MN-microglia dialogue pathways CXCR3-CCL21; CX3CR1-CX3CL1 
and MFG-E8 are increased. Proliferation marker Ki-67 and autotaxin levels are elevated. Inflammation-related 
molecules IL-18, HMGB1 and NLRP3 expression levels are increased.   
Future Perspectives 
In our study we were able to identify key pathophysiological aspects of the ALS using the mSOD1 
study model. Further investigation aims to evaluate new cellular and molecular markers that will pro-
vide insight into (de)differentiation state of glial cells along with better understanding of the molecular 
pathways involved in ALS onset and progression. Additional work should focus on glutamate trans-
porters, due to glutamate excitotoxicity being described an important cause for neuronal death. As well 
as emphasis in inflammatory-related markers such as IL-1β and NF-κB for better understanding of the 
major aspects of the inflammatory pathway are altered. 
Moreover, studies require the evaluation of these molecules through an immunohistochemistry ap-
proach in order to assess proliferation patterns and communication pathways involved as well as phe-
notypic characterization of the cells studied. 
Finally, our approach could be further applied to other known brain regions affected in ALS, namely 
the motor cortex which could provide a better understanding of the location where the disease begins 
(Eisen and Weber, 2001) as there is controversy on “dying back” versus “dying forward” mechanisms 
leading to the disease (Redler and Dokholyan, 2012). As these studies could provide better under-
standing of the development of cortical and spinal motor neuron populations, their interaction with 
each other, and how it changes in ALS as well as the identification of the earliest, presymptomatic 
characteristics of ALS possibly providing new biomarkers for earlier diagnosis. 
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Annex 1.1. 
 
 
 
Figure VI.1. HMGB1 protein expression does not change in 
the spinal cord (SC) of presymptomatic mSOD1 mice when 
compared to aged-matched controls (WT). Samples were 
treated as indicated in Methods. Results are expressed as mean 
(± SEM) from at least three independent experiments *p<0.05 vs. 
matched WT mice using two-tailed unpaired Student´s t-test. 
 
 
Annex 1.2. 
 
 
Figure VI.2. HMGB1 protein expression does not change in the 
spinal cord (SC) of symptomatic mSOD1 mice when compared 
to aged-matched controls (WT). Samples were treated as 
indicated in Methods. Results are expressed as mean (± SEM) 
from at least three independent experiments *p<0.05 vs. matched 
WT mice using two-tailed unpaired Student´s t-test. 
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Exploring the pro-inflammatory environment in the spinal cord of mutant SOD1G93A mice: po-
tential biomarkers at pre- and symptomatic phases 
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Neuroinflammation is a key hallmark of amyotrophic lateral sclerosis (ALS), a severe motoneuron 
disease. Accumulating evidence suggest the involvement of glial cell activation during disease pro-
gression, although the features involved in each specific disease stage are still elusive. Since both 
diagnosis and treatment of ALS remain scarce, attempts to find novel disease biomarkers and thera-
pies are imperative. 
Here we aimed to identify potential inflammatory-related biomarkers that may differentiate ALS 
stages and constitute targets for therapeutics. We have performed a RT-PCR-based study using lum-
bar spinal cord (LSC) tissue of the TgSOD1G93A mice (mSOD1), the most used ALS model. Samples 
were collected at 4-5 weeks-old (presymptomatic stage, PS) and 14-16 weeks-old mice (symptomatic 
stage, S). Non-tg mice were used as controls.  
Analysis of mSOD1 mice LSC indicated that autotaxin and CCL21 were reduced at PS phase 
(0.8-fold and 0.3-fold, respectively, p<0.05) and increased at S stage (4-fold and 3-fold, respectively, 
p<0.05). The alarmin high mobility group box-1 (HMGB1) followed such profile, i.e., low levels at PS 
(0.4-fold, p<0.05) and elevated ones at S (10-fold, p<0.01), revealing that a pro-inflammatory envi-
ronment courses with defensive mechanisms as disease progresses. Regarding CX3CL1-CX3CR1 
axis, we observed that the cytokine was down-regulated at PS phase (0.3-fold, p<0.05) increasing 
thereafter (~4-fold, NS), while its receptor was only up-regulated at S stage (5-fold, p<0.05). Also in-
creased at S phase were the inflammatory-associated proteins Cx43 (5-fold, p<0.05), TLR2 (3-fold, 
p<0.05) and the inflammasome component NLRP3 (6-fold, p<0.01). By determining the inflammatory 
miRNA (miR) profiling, we noticed that miR-155 was already up-regulated at PS phase (1.6, p<0.05) 
while miR-124 and miR-146a were only up-regulated at S stage (1.4-fold and 3.8-fold, p<0.05).  
Our results suggest that decreased autotaxin expression and increased miR-155 are features of 
the PS stage, and precede the network of pro-inflammatory-related symptomatic determinants that 
include HMGB1, CCL21, CX3CL1, miR-124 and miR-146a. We hypothesize that by increasing auto-
taxin expression and down-regulating miR-155 expression we may be able to delay ALS onset, before 
considering anti-inflammatory compounds to fight disease progression.  
Supported by grants PTDC/SAU-FAR/118787/2010 (DB) and PEst-OE/SAU/UI4013/2013-2014, 
and by the fellowship SFRH/BD/91316/2012 (CC) from Fundação para a Ciência e a Tecnologia. 
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Abstract  
Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by the selective loss of 
motor neurons, although glial cells seem to be required for the disease initiation and/or progression. 
We are investigating how microglia phenotypes and activation stages may influence motor neuron de-
generation. For that we use primary cultures of cortical microglia isolated from transgenic mice carry-
ing the mutant human G93A superoxide dismutase 1 gene, as well as spinal cord homogenates from 
such mice. We observed that microglia reactivity differs from the presymptomatic to the symptomatic 
stage. 
 
 
